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1Introduction and aims of the thesis
The evidence of excess cardiovascular disease (CVD) risk in rheumatoid arthritis (RA) is 
mounting and this risk may even be as high as in patients with type 2 diabetes mellitus 
(T2DM) (1-3). Initial research regarding the excess CVD risk in RA was focussed on the ongo-
ing inflammation in RA. Since inflammation is a key factor in the development of atheroscle-
rosis, RA-associated inflammation may contribute to the increased CVD risk. Several studies 
showed that elevated inflammatory parameters such as C-reactive protein and erythrocyte 
sedimentation rate are associated with the increased CVD risk (4, 5). More recently the tradi-
tional CVD risk factors, such as hyperlipidemia, hypertension, diabetes mellitus and smoking 
have gained more interest in RA. However, the exact contribution of traditional CVD risk 
factors in the development of CVD in RA is unclear. It is also not known if treatment of these 
traditional risk factors influences the course of development of CVD in RA (5).
The FRANCIS study
All the research of this thesis is based on the FRANCIS study, which is a prospective, 
randomized clinical trial in RA patients investigating the potential benefit of strict cardio-
vascular risk reduction compared to standard care. RA patients younger than 70 years of 
age and without clinical CVD or T2DM were eligible. CVD was defined as a prior myocardial 
infarction, cerebrovascular event, amputation due to peripheral artery disease, intermit-
tent claudication, percutaneous transluminal coronary angioplasty (PTCA) or coronary 
artery bypass graft (CABG). T2DM was defined as fasting glucose >7.0 mmol/l. All patients 
at inclusion were routinely screened for traditional CVD risk factors at the Diabetes and 
Vascular Centre, Franciscus Gasthuis, Rotterdam, the Netherlands. After inclusion patients 
were either randomized to intensive treatment of traditional CVD risk factors at the Diabe-
tes and Vascular Centre, of the Franciscus Gasthuis, with pre-specified treatment targets 
and recommendations on lifestyle changes or they were randomized to usual care and 
referred to their general practitioner for further treatment. All patients visited the outpa-
tient clinic routinely every six months (which is similar to the appointments of the usual 
care group), but extra appointments were made when necessary for patients in the tight 
control group. Before randomization the CVD risk score according to the 2010 unadjusted 
SCORE risk assessment was calculated. The SCORE risk assessment estimates the 10 year 
risk of fatal CVD risk based on sex, age, smoking, blood pressure and the total cholesterol/
HDL-cholesterol ratio (Figure 1) (6). Patients with a CVD risk score <10% were eligible for 
randomization (comparable to <20% in the currently used, unadjusted SCORE table that 
also includes non-fatal CVD (7)). Patients with a CVD risk score ≥10% were followed in a 
separate cohort and treated according to the tight control protocol. 
The primary objective of the FRANCIS was to investigate whether a tight cardiovas-
cular risk reduction program is effective in reducing progression of the intima media 
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thickness, a marker for subclinical atherosclerosis, in patients with RA compared to usual 
care. The follow-up was set at fi ve years and will be completed in all participants at the 
end of 2017. Results discussed in this thesis are reports of baseline data, subanalyses 
and interim analyses.
The main objectives of this thesis
1. To determine the prevalence and impact of traditional CVD risk factors such as 
hypertension and hyperlipidemia on CVD risk and (subclinical) atherosclerosis in RA 
patients that do not have a history of CVD or diabetes mellitus. 
2. To determine patients believes on adherence to their advised CVD preventive treat-
ment. 
3. To explore the presence of postprandial dyslipidemia, as a novel risk factor, in RA 
patients. 
Figure 1. The unadjusted SCORE model to calculate the 10-year risk of fatal cardiovascular disease (6).
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1Outline of the thesis
The main focus of this thesis is on the role of traditional CVD risk factors on CVD in RA; 
their prevalence, their association with subclinical atherosclerosis and whether a tight 
treatment protocol on CVD risk factors results in improved treatment of traditional CVD 
risk factors. The current evidence concerning RA and CVD is reviewed in Chapter 2. In 
Chapter 3 we investigated the prevalence of traditional CVD risk factors in the FRANCIS 
population, using the SCORE model and two suggested modified SCORE models by the 
European league against rheumatism (EULAR) and the Dutch guideline for CVD risk 
management (7, 8). These modifications of the SCORE model are shown in Table 1. 
The aim was to investigate the prevalence of underdiagnosis and undertreatment of 
hypertension and hyperlipidemia in RA.
In the general population, the cornerstone of CVD risk reduction is lifestyle recommen-
dations like following a healthy diet, cessation of smoking and performing daily exercise. 
We know that patients adherence to lifestyle recommendations and drug therapy for 
preventive measures is generally low (9). One of the explanations may be that patients 
perspectives regarding CVD risk may be different compared to doctors perspectives. In 
order to evaluate the perspective of the FRANCIS patients regarding strategies for CVD 
risk reduction and their adherence, all patients in the tight control arm received a ques-
tionnaire to address this matter. The results of this study are described in Chapter 4.
Atherosclerosis is a slowly progressive disease, which remains asymptomatic for many 
years before clinical CVD becomes evident. CVD presents as angina pectoris, myocardial 
infarction, a stroke or as intermittent claudication, but the atherosclerotic process is 
already on-going for years before clinical symptoms occur. A commonly used measure-
ment for the detection of subclinical atherosclerosis is the measurement of the carotid 
intima media thickness (cIMT). A recent meta-analysis by Wang et al. showed that the 
cIMT is increased in RA compared to healthy controls. Furthermore, in RA there is an 
increased progression rate of cIMT described compared to controls (10). In Chapter 5 we 
Table 1. National and international guidelines for CVD risk assessment in RA patients.
Adaptations to CVD risk assessment according to SCORE
EULAR guideline (2010) CVD risk* x 1.5 if at least two of following characteristics 
are present:
- > 10 years RA disease duration 
- RF and/or anti-CCP positivity 
- severe extra articular disease 
Dutch guideline for CVD risk management (2011) Age +15 years for all RA patients**
* According to SCORE and/or Framingham
** For assessment of CVD risk according to SCORE 
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investigated the association of several traditional and RA-specific CVD risk factors with 
cIMT and compared these results with healthy controls.
Since traditional and RA-specific CVD risk factors cannot fully explain the excess CVD 
risk in RA search for novel CVD risk factors in RA is warranted. In Chapter 6 we therefore 
investigated apolipoprotein B48 levels, the structural protein of chylomicrons and a 
marker of postprandial lipemia, in RA patients. Postprandial lipemia is of exceptional 
interest since it is linked to both inflammation and the traditional risk factor hyperlipid-
emia.
Besides searching for new and RA specific CVD risk factors it is important to investi-
gate the effect of treatment of traditional CVD risk factors. There is no reason to believe 
that treatment of traditional CVD risk factors is of less importance than they are in the 
general population, but it is unknown whether they should be treated with extra atten-
tion and intensity in RA like in diabetes mellitus or patients with known CVD. Chapter 
7 describes the results of strict CVD risk reduction versus standard care in RA after two 
years of follow-up, which is an interim analysis of the original planned follow-up of 5 
years. 
Finally, the results of the performed studies will be discussed and reflected upon 
in Chapter 8. Recommendations will be made for clinical practice and the remaining 
uncertainties, which need future explorations, will be described. 
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Summary
Patients with rheumatoid arthritis (RA) carry an excess risk for cardiovascular disease, 
which is comparable to the risk in patients with type 2 diabetes mellitus. The mecha-
nisms involved are partly related to traditional cardiovascular risk factors, disease-
associated inflammation and undertreatment of traditional cardiovascular disease 
(CVD) risk factors. Since atherosclerosis is an inflammatory disease, the auto-immune 
mediated inflammation observed in RA patients contributes to increased endothelial 
dysfunction, oxidative stress and activation and vascular migration of leukocytes. This 
concept is underscored by the CVD risk reduction that is seen by anti-inflammatory 
disease modifying anti-rheumatic drugs such as methotrexate and TNFα inhibitors. The 
evidence for underdiagnosis and undertreatment of traditional CVD risk factors in RA 
strengthens the potential benefit of structured CVD risk management in these patients. 
Current cardiovascular guidelines recommend screening and treatment of CVD risk fac-
tors in RA patients, without well defined treatment targets. At present, there is a lack of 
scientific evidence to establish treatment targets for CVD risk factors in RA. Therefore, 
expanding research regarding screening and treatment of traditional CVD risk factors in 
RA patients is needed. 
Introduction
The evidence on the excess of cardiovascular disease (CVD) risk in rheumatoid arthritis 
(RA) has accumulated during the last two decades (1-3). It has been suggested that the 
prevalence of CVD in patients with RA is as high as in patients with type 2 diabetes mel-
litus (1). Interestingly, the increased CVD risk observed in RA may be independent from 
traditional risk factors for CVD (1, 4). These risk factors such as dyslipidemia, hyperten-
sion, smoking and obesity have been found in patients with RA in a similar frequency 
as in the general population (5, 6). It has been shown that these traditional risk factors 
contribute to the development of atherosclerosis in RA, but their presence alone can not 
fully explain the increased CVD risk (7, 8). 
RA-specific factors, such as rheumatoid factor (RA) and/or anti-CCP positivity, joint 
erosions and extra-articular RA have been linked to the development of premature 
atherosclerosis in this condition. Since atherosclerosis is an inflammatory disease, it has 
been proposed that the increased inflammatory state of patients with RA explains, at 
least in part, the increased CVD risk (2, 4, 6, 7, 9). Furthermore, joint damage and physical 
inactivity are common in patients with RA and have been associated with an increased 
prevalence of CVD (8). In addition, RA is treated with different disease modifying drugs 
(DMARDs), with anti-inflammatory effects and with potential anti-antherosclerotic con-
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sequences(8). To date, the exact contribution of all of these factors to the development 
of premature atherosclerosis in RA remains unclear. There is need for studies investigat-
ing the pathogenesis of atherosclerosis in RA and a well defined treatment protocol 
to lower the excess CVD risk is warranted. The purpose of this review is to provide an 
overview of the current evidence concerning the major determinants of excess CVD risk 
and the optimal CVD risk management in RA and to explore future scientific directions.
RA, inflammation and atherosclerosis
The formation of an atherosclerotic plaque takes place in different stages, which are 
driven by deposition and oxidation of lipids in the subendothelial space, activation of 
leukocytes and endothelial cells and finally thrombosis (Figure 1) (10). 
All apolipoprotein (apo) B containing lipoproteins e.g. chylomicrons, chylomicron 
remnants, very low density lipoproteins (VLDL), intermediate density lipoproteins (IDL) 
and low density lipoproteins (LDL) can enter the subendothelial space via disrupted tight 
junctions between altered endothelial cells (11, 12). These lipoproteins can be taken up 
by macrophages converting them to foam cells. LDL needs to become oxidized (oxLDL) 
before it can induce foam cell formation, whereas chylomicrons and their remnants do 
not need modification (13). There is evidence that tumor necrosis factor alpha (TNFα) 
can directly stimulate the oxidation of LDL (14), and it has been observed that oxLDL 
levels are higher in patients with RA (15). Moreover, increased oxLDL concentrations 
have been linked to increased RA disease activity (15). The oxidation of LDL is catalysed 
by lipoprotein associated phospholipase A2 (Lp-PLA2) (16), but its precise contribution 
to the development of atherosclerosis in RA is uncertain since reduced levels of Lp-PLA2 
have been observed in RA (17), whereas increased Lp-PLA2 activity has been found in 
association with CVD (18). 
Lp(a), which is a pro-atherogenic lipoprotein that consists of an LDL-like particle and 
apo(a), can become oxidized and provoke an immune response similar to oxLDL. Apo(a) 
promotes thrombosis and inhibits fibrinolysis due to its homology with plasminogen 
(19, 20). An increase in Lp(a) has also been associated with inflammation, but data are 
inconsistent (21-23). Lp(a) is an independent risk factor for CVD (20) that may be dispro-
portionally elevated in RA (19, 21, 22). 
A key event in the development of both atherosclerosis and RA is inflammation (10, 
24). Pro-inflammatory cytokines like TNFα and interleukin-6 (IL-6) are produced by the 
synovial tissue and play a key role in both the pathogenesis of RA and the development 
of atherosclerosis (25). One of the effects of TNFα is an increase in monocyte activation 
and cytokine release (25, 26). IL-6 causes T and B-cell proliferation and recruitment of 
neutrophils, all of which are involved in tissue damage in RA and development of the 
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atherosclerotic plaque and subsequent risk of plaque rupture (10, 25). Both, IL-6 and 
TNFα levels are elevated in RA (Table 1). The release of pro-inflammatory cytokines 
from the synovial tissue induces systemic inflammation triggering all these events (25). 
These circulating cytokines may also cause inflammatory changes in the adipose tissue 
resulting in an increased production of adipokines leading to a further enhancement 
of systemic inflammation (Table 1) (11, 27). Macrophages present atherogenic antigens 
against oxLDL or apolipoprotein (apo) B to CD4+ T cells, resulting in chemo attraction 
of leukocytes, T-cell proliferation and production of TNFα and interferon-γ (IFN-γ) (28, 
29). These pro-inflammatory cytokines induce lipid uptake by macrophages (28, 30). In 
addition, macrophage activation leads to increased expression of endothelial leukocyte 
adhesion, resulting in higher adherence of monocytes and T-lymphocytes and secretion 
of pro-inflammatory cytokines such as IL1-α, IL1-β, and TNFα (31).
Specific CD4+ T cells, which are deficient for CD28, secrete high levels of pro-inflam-
matory cytokines and due to their capacity to infiltrate unstable atherosclerotic plaques 
can cause plaque rupture (32). CD4+ CD28- T cells are more often present in RA compared 
to healthy subjects (64% vs. 45%, P=0.02) (33). These cells also have been associated 
with increased extra-articular manifestations of RA and with endothelial dysfunction 
and subclinical atherosclerosis (34, 35). Eventually, all these processes contribute to a 
state of chronic inflammation and the premature development of atherosclerosis in RA 
(Figure 1).
RA specific alteration in high density lipoprotein function
High density lipoproteins (HDL) exert an atheroprotective effect via reverse cholesterol 
transport together with their anti-inflammatory, anti-oxidant and anti-thrombotic prop-
erties (36-38). Therefore, the pathofysiological association between HDL and CVD risk is 
complex. Several studies have shown that HDL function is impaired in RA and HDL may 
even express pro-inflammatory characteristics in up to 20% of RA patients (36). 
Using mass spectrometry, 85 different proteins have been identified on HDL (37). Sur-
prisingly proteomic profiling of HDL in active RA showed an increase in pro-inflammatory 
proteins including fibrinogen and several complement factors (C3, C9 and factor B) (39). 
Interestingly, the cholesterol efflux capacity of HDL by the ATP-binding cassette 
transporter G1 (ABCG1), which is crucial for cholesterol efflux from hepatocytes to lipid 
poor HDL is impaired (40). These results were confirmed by other investigators (41). In 
RA higher serum levels of myeloperoxidase (MPO) correlated with a reduction in HDL 
cholesterol efflux capacity and this was accompanied by a reduction in the anti-oxidant 
function of HDL (41).
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The RA-associated alterations in HDL function including its impaired cholesterol efflux 
capacity, a shift from anti-inflammatory to pro-inflammatory properties and a reduction 
in its anti-oxidant capacity may all contribute to the increased CVD (38).
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Figure 1. The inflammation-driven atherogenicity of rheumatoid arthritis (RA). Release of pro-inflamma-
tory cytokines from the synovial tissue in RA has direct effects on systemic inflammation and the initiation 
of atherosclerosis. The released cytokines modulate the function of the endothelium, leukocytes and the 
oxidation of lipoproteins. Oxidation of low-density lipoproteins (LDL) can be initiated by TNFα and reactive 
oxygen species (ROS), inducing uptake by macrophages, converting them into foam cells when cholesterol 
influx exceeds cholesterol efflux. Native chylomicron remnants (Rem) can be taken up by macrophages 
without modification leading to foam cell formation. Macrophages present atherogenic antigens like ox-
LDL to CD4+ T cells, which attracts additional leukocytes and leads to T cell proliferation and production 
of more TNFα and interferon-γ (IFN-γ). These proinflammatory cytokines, and triglyceride-rich lipoproteins 
(TRL), which include chylomicrons, chylomicron remnants and VLDL, activate monocytes and neutrophils, 
promote additional lipid uptake by macrophages and increased expression of cellular adhesion molecules 
(CAM) on the endothelium, which further attracts monocyte derived macrophages and T-lymphocytes and 
the expression of pro-inflammatory cytokines such as IL1-α, IL1-β, and anti TNFα (31). All these enhanced 
cascades in RA contribute to chronic inflammation and the premature development of atherosclerosis in 
RA.
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RA and markers of subclinical atherosclerosis
Atherosclerosis is a slowly progressive disease, which remains asymptomatic for many 
years before clinical CVD becomes evident. The first stages of subclinical atherosclerosis 
include endothelial dysfunction and the formation of fatty streaks and atherosclerotic 
plaques, which result in increased arterial stiffness and thickening of the intima and 
media of the arterial wall (42). There are several surrogate markers of atherosclerosis 
available such as flow mediated dilatation (FMD), augmentation index (AIx), pulse wave 
velocity (PWV), carotid intima media thickness (cIMT), the coronary artery calcification 
score (CAC) and computed tomography angiography (CTA). Data on these surrogate 
markers of atherosclerosis in RA have been summarized in Table 2. Overall, a decrease 
in FMD and an increase in AIx and PWV have been reported in RA-patients, suggesting 
endothelial dysfunction (43-48). Inflammation during the early course of RA, which is 
characterised by increased CRP concentrations, has been associated with increased 
arterial stiffness (measured by PWV and AIx) after 15 years of follow up (49). Several 
studies have shown increased cIMT and formation of plaques within the carotid artery in 
RA patients, which was already observed early in the disease when compared to non-RA 
Table 1. RA mediated changes in cellular adhesion molecules, cytokines and chemokines associated with 
the development of atherosclerosis
Cytokines, chemokines, 
adhesion molecules
Changes in RA Atherogenic effect
CRP 25% of RA patients have 
CRP>10mg/L (4) 
Activation of inflammatory cells (11)
TNFα Increased with 62% (61) Local and systemic inflammatory response 
(11) and increased VCAM-1 expression (146)
IL-6 Three-fold increased (61) Local and systemic inflammatory response
E-selectin 20-43% increased (61, 147, 148) Adherence of leukocytes to endothelium
sVCAM-1 May be increased, but data are 
inconsistent (61, 147-150) 
Endothelial adhesion of leukocytes
sICAM-1 7-115% Increased (61, 147, 148, 150) Endothelial adhesion of leukocytes
sTF Almost three-fold increased (151) Endothelial cells and leukocytes; initiates 
coagulation cascade
VEGF Both an increase (149) as well as no 
change have been reported (61)
Endothelial permeability, pro-angiogenic
Angpt-2 Increased (149) Upregulation of growth factors, cytokines 
and chemokines
MPO 33% increased (61) Produces cytotoxic agents during respiratory 
burst of neutrophils
CRP = C-reactive protein; sTF = soluble tissue factor; Angpt-2 =angiopoetin-2; VEGF = vascular endothelial 
growth factor; TNFα = Tumour Necrosis Factor-α; ICAM-1 = intercellular adhesion molecule-1; MPO = my-
eloperoxidase; IL = interleukin; CAC = coronary artery calcium score
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controls (43, 44, 50). However, a small cohort study of 105 RA patients did not identify 
cIMT as a predictor for future cardiovascular events (51). Recently, van Sijl et al. showed 
no differences in cIMT between RA patients and healthy controls. They described a mal-
adaptive outward carotid arterial remodelling, which plays an important role in plaque 
instability and rupture, but this is not measured using the regular cIMT technique (52). 
Both, in the general population and in RA patients the presence of carotid artery 
plaques increase the CVD risk (51, 53). The presence of vulnerable plaques, with a thin 
fibrous cap, a larger lipid core and infiltration of inflammatory cells, increases the CVD 
risk even more. Patients with RA have more carotid plaques than the general population 
(54, 55) and RA patients had more vulnerable plaques when compared to controls (56). 
CTA can be used to visualize soft, non-calcified plaques and the presence of stenotic 
arteries like the coronary and carotid arteries. Since carotid plaques are recently shown 
to be a predictor of poor cardiovascular survival, CTA may provide additional accuracy 
in CVD risk prediction in RA.
With the improvement of Computed Tomography, CAC is an established, non-invasive 
instrument to measure the atherosclerotic burden. CAC has a high sensitivity and nega-
tive predictive power for obstructive coronary artery disease, but the specificity of CAC 
is limited (57). The ability of CAC to predict future coronary events in symptomatic per-
sons has been proven in several studies (57). The severity of coronary artery calcification 
has been found to be increased in RA patients compared to controls (58, 59). However, 
Chung et al. did not find a significant difference in CAC between early RA patients (less 
than 5 years after diagnosis) and healthy controls (58). These results suggest that the 
development of coronary calcifications may depend on the duration of RA. 
In addition to functional tests, also circulating markers of endothelial function such 
as E-selectin, vascular and intercellular cell adhesion molecules have been proposed as 
markers of endothelial dysfunction (42). Increased plasma levels of these molecules have 
been observed in RA, but there was no correlation between several adhesion molecules 
and CVD risk or subclinical markers of atherosclerosis (Table 1) (60-62). 
Prevalence of traditional cardiovascular risk factors in RA
Research on atherosclerosis in RA patients for the last 25 years has focussed on inflam-
mation (31). In our opinion, traditional CVD risk factors need to be addressed in RA 
since the prevalence in RA may be as high as in patients with diabetes mellitus, which is 
known for its increased frequency of hypertension and dyslipidemia (63).
As known, smoking is one of the most important environmental risk factors for the 
development of CVD, but smoking is also known as a risk factor for the development 
of RA and accounts for approximately 25% of the risk to develop the disease (64). This 
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risk for developing RA is dose dependent and even higher in anti-citrullinated peptide 
antibody (ACPA) positive RA patients (65-68). Smoking is therefore frequently seen in 
RA populations and may provide a potential bias in studies on RA and CVD. A recent 
meta-analysis by Sugiyama et al. showed that the prevalence of ever, current and past 
smokers in RA was as high as 50.6%, 26,5% and 26,3%, respectively (66). 
There is also a complex relation between obesity, RA and CVD. In RA patients, obesity 
results in higher RA disease severity, increased swollen joint count and higher work 
disability (69, 70). Besides the negative impact on RA itself, obesity is associated with 
cardiovascular morbidity and mortality (71, 72). Similar associations between obesity 
and CVD have also been found in RA (70, 73, 74). A different effect of a low body mass 
index (BMI) on CVD mortality in RA has also been suggested. The incidence in CVD mor-
tality for RA patients with a BMI below 20 kg/m2 is increased compared to the general 
population (75). A possible explanation of this increased CVD risk is that a low BMI in 
RA patients may indicate the presence of rheumatoid cachexia. This condition reflects 
predominantly a loss of skeletal muscle and is, among others, mediated by an increased 
production of pro-inflammatory cytokines (76). Furthermore, RA patients are less active 
than their healthy counterparts and physical inactivity in RA has been associated with 
an increased arterial stiffness (77). 
Several studies have shown an underdiagnosis and undertreatment of traditional CVD 
risk factors, such as hypercholesterolemia and hypertension in RA (78-80). Hyperten-
sion is common in RA, with a prevalence ranging from 57% to 70.5% and hypertension 
is frequently not optimally controlled in RA (78, 79). In these studies, 40% to 45% of 
RA patients with hypertension did not reach target blood pressure levels as defined in 
current therapeutic guidelines (i.e. a systolic blood pressure of ≤ 140mmHg and/or a 
diastolic blood pressure of ≤ 90mmHg) (78, 79). Panoulas et al. showed that 32% of RA 
patients with target organ damage (defined as described in the European guideline for 
management of arterial hypertension) had undiagnosed hypertension (78). RA itself 
can be seen as a risk factor for the development of hypertension. As described earlier, 
the RA associated inflammatory state may activate the endothelium, which can lead to 
endothelial dysfunction, inhibition of the vasodilatory function, vascular calcification 
and therefore increased central blood pressure (31, 45, 81). 
In the inflammatory state of RA, cholesterol levels, which include HDL-C, LDL-C and 
total cholesterol, may be suppressed (82). However, HDL-C concentrations are more 
suppressed in RA than the atherogenic LDL-C, which results in a more atherogenic 
lipid profile (29, 82, 83). This might be the explanation why several investigators found 
that lower cholesterol levels were associated with increased CVD risk in RA (84, 85). 
Furthermore, these studies did not take into account the heterogeneity of HDL function 
as described earlier. Interestingly, a decrease in total cholesterol and LDL-C, but not in 
HDL-C, can already be observed 5 years prior to the diagnosis of RA (86). The mechanism 
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behind these changes, which are different from the changes during active RA disease, is 
not fully understood. It is believed that the inflammatory state, which is present prior to 
diagnosis, plays an important role (86). Serum apo B levels and the number of circulating 
chylomicrons are higher in RA patients when compared to age matched healthy controls 
(87). Knowlton et al. measured lipid profiles as well as apolipoproteins in 152 RA patients 
and determined the coronary artery calcification score at baseline and after 3 years 
of follow-up. They showed that RA patients with progression in CAC had significantly 
higher total cholesterol/HDL-C, higher levels of apo B and a higher number of circulating 
chylomicrons compared to RA patients that did not show any CAC progression (88). No 
differences in plasma apo A-I levels were found. 
Drug related cardiovascular risk factors in RA
Non-steroidal-anti-inflammatory-drugs (NSAIDs) and oral glucocorticoids are widely 
prescribed in RA, which are both associated with the development of hypertension 
(78, 89-91). A recent meta-analysis by Trelle et al. evaluated several NSAIDs in relation 
to myocardial infarction, stroke, cardiovascular death. They found that cardiovascular 
profiles of individual NSAIDs varied considerably. Overall naproxen seemed less harmful 
regarding cardiovascular risk when compared to other NSAIDs (91). The exact mecha-
nism by which NSAIDs increase the risk of a cardiovascular event is not fully understood. 
The degree of blocking of cyclooxigenase-2 is suggested to play an important role in the 
cardiovascular risk profile of an individual NSAID (92, 93). 
Regarding glucocorticoïds, Aviña-Zubieta et al. recently showed an increased risk for 
myocardial infarction in current users (94). No significant correlation between cerebral 
vascular disease and the use of glucocorticoïds was found (95). The contribution of 
glucocorticoïds to CVD risk is believed to be dose dependent (94).
Cardiovascular risk prediction in RA
The most widely used risk scores for the prediction of CVD are the Framingham Risk 
Score and the SCORE model (96, 97). These risk models are based on traditional CVD risk 
factors in non-high risk populations, but they do not take into account the excess CVD 
risk observed in RA patients. Because of the mounting evidence regarding the excessive 
CVD risk in RA and the lack of precise management and risk stratification in RA, the 
European League Against Rheumatism (EULAR) published in 2010 recommendations 
for CVD risk management specifically for RA and other forms of inflammatory arthritis 
(98). EULAR recommends an annual risk assessment for all RA patients using national 
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guidelines. A first attempt to adapt the traditional SCORE model (97) and Framingham 
Risk Score (96) for RA patients was made, to correct for the underestimated CVD risk 
(Table 3). This modification includes a multiplication of the measured CVD risk (with 
the use of SCORE or the Framingham Risk Score) by a factor of 1.5 for patients with RA 
and two of the following three criteria: RA disease duration >10 years, the presence of 
rheumatoid Factor (RF) or anti-CCP and/or presence of severe extra-articular manifesta-
tions (98). However, the criterion of disease duration of >10 years is debatable because 
recent publications have shown that the risk for cardiovascular morbidity and mortality 
is already increased shortly after the diagnosis of RA, which underscores the importance 
of early intervention (43, 99). In addition, Finck et al. showed that the addition of RF 
or anti-CCP to the traditional FRS did not improve the accuracy of CVD risk prediction 
in RA patients (100). Despite these shortcomings, the EULAR has made a first attempt 
to improve CVD risk assessment in RA. In our opinion, clinical trials are necessary to 
establish the validity of these recommendations. 
The 2011 Dutch guideline for CVD risk management also suggests to adapt the 
standard risk assessment tool in RA patients (101). It was advised to add 15 years to 
the age of RA patients when establishing their risk according to the SCORE table (Table 
3). However, once again evidence for this approach is lacking. The recently developed 
guideline for the management of dyslipidaemias from the European Atherosclerosis 
Society (EAS) and European Society of Cardiology (ESC) recognises RA as a risk factor for 
the development of atherosclerosis but does not provide specific recommendations for 
CVD risk assessment in the case of RA (Table 3) (98, 102). Therefore, further research to 
develop an accurate risk assessment tool with treatment recommendations aimed at RA 
is necessary. In the mean time risk stratification might be improved by the combination 
of risk assessment tools with atherosclerotic imaging.
Table 3. Overview of national and international guidelines for CVD risk assessment in RA patients.
Adaptations to current CVD risk assessment
EULAR CVD risk* x 1,5 when at least two of following 
characteristics are present:
- > 10 years RA disease duration 
-RF and/or anti-CCP positivity 
- severe extra articular disease 
Dutch guideline for CVD risk management Age +15 years for all RA patients**
EAS guideline for dyslipidaemia No adaptations
* According to SCORE and/or Framingham
** For assessment of CVD risk according to SCORE 
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Treatment of traditional cardiovascular risk factors in RA
Treatment of traditional CVD risk factors is the cornerstone of successful CVD risk reduc-
tion in the general population (102). In our opinion, awaiting further studies, this is also 
the case in RA. Treatment of CVD risk factors includes both, lifestyle modification and 
pharmaceutical interventions.
Exercise is in the general population an important behavioural strategy for CVD 
prevention, but also in RA patients (103). It has been shown that an individualized 
exercise training program, which consisted of a 6 months tailored aerobic and resis-
tance exercise intervention, improved endothelial function in patients with RA (104). 
RA guidelines emphasize indeed the role of exercise and physical activity, but they do 
not provide clear recommendations (105). More studies are necessary to investigate the 
effect of exercise in reducing CVD risk in RA and to provide clear recommendations for 
RA patients. Dietary advice may include a traditional low-fat diet or a Mediterranean 
diet. The Mediterranean diet is rich in omega-3-fatty acids as opposed to predominantly 
omega-6-fatty acids in western diets and has been shown to reduce cardiovascular risk 
(106). Besides their protective role in cardiovascular disease, omega-3-fatty acids reduce 
inflammation in chronic inflammatory diseases such as RA (107, 108).
Pharmaceutical interventions are the next step in CVD risk prevention after improving 
lifestyle. A recent study showed that patients with inflammatory joint disease receiving 
statin therapy had a comparable decrease in cholesterol levels and CVD risk reduction as 
patients without inflammatory joint disease (109). This is further illustrated by De Vera et al. 
who showed that discontinuation of statin therapy in RA patients who already used statins 
was associated with increased cardiovascular mortality (HR 1.41, 95% CI 1.02-1.96) (110). 
Statin therapy successfully lowers LDL-C and CVD risk (Table 4), but the benefit of treatment 
in primary prevention depends on age and other risk factors. Uncertainty exists when to 
initiate lipid lowering therapy in RA patients for primary prevention. The Dutch guideline 
for CVD risk management 2011 recommends to treat RA patients similarly as patients 
with diabetes mellitus, suggesting early and intensive lipid lowering therapy with LDL-C 
treatment targets of 2.5 mmol/l (101). Recently, Rollefstad et al. showed that a structured 
approach and treatment to target is possible in patients with inflammatory joint disease 
since 90% of the study population (n=426) was successfully treated to lipid targets (80). 
Besides their lipid lowering effect, statins also have anti-inflammatory properties (111, 
112). The Jupiter trial showed that rosuvastatin significantly reduced the incidence of 
major cardiovascular events in apparently healthy persons without hyperlipidemia, but 
with elevated high-sensitivity CRP levels (112). These data suggest that the beneficial 
effects of statins are more than just LDL-C lowering and that the anti-inflammatory role 
of these drugs may also contribute to CVD risk reduction. However, others have shown 
that, in non-RA patients, most of the CVD risk reduction by statins can be accounted for 
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by the LDL-C reduction and not by these so called (anti-inflammatory) pleiotropic effects 
(113). In addition to the lipid lowering effect, reduction of RA disease activity on statin 
therapy has also been described (114). El Barbary et al. showed that atorvastatin in RA 
resulted in a marked reduction in RA disease activity, a more advantageous atherogenic 
index and improved endothelial function (115). However, the opposite has also been 
described. A recent study with an arthritis mouse model by Vandebriel et al. showed 
that treatment with atorvastatin or pravastatin accelerated arthritis onset and resulted 
in a higher prevalence of arthritis compared to non-statin using mice (116). These results 
confirm previous reported associations of statin use and the development of RA in ob-
servational studies (117). Whether these associations outweigh the beneficial effect of 
statins on atherosclerosis in RA is not yet clear. Prospective studies on the use of statins 
in RA are lacking. Therefore, we feel that routinely prescription of statin therapy to RA 
patients regardless their lipid profile is not justifiable. Whether the treatment target for 
LDL-C of 2.5mmol/L is justifiable, remains to be investigated in prospective studies.
Strict regulation of blood pressure with treatment targets of a systolic blood pres-
sure ≤140 mmHg have been recommended in all patients including patients with RA 
(101), although prospective data on strict blood pressure regulation in RA patients are 
lacking. It is important to perform blood pressure measurements on a routine basis to 
properly diagnose hypertension in RA patients (118). Especially since small increases 
in systolic blood pressure (1-5 mmHg) have already been associated with an increased 
CVD risk (119). However, there are limited data available regarding the preferred antihy-
pertensive agents in specifically RA. There is some evidence that angiotensin converting 
enzyme (ACE) inhibitors may be beneficial in RA. Flammer et al. showed that 8 weeks of 
treatment with ACE-inhibitors improved endothelial function (assessed by FMD of the 
brachial artery) in RA patients, together with a reduction in CD40, which is an important 
inflammatory mediator and member of the TNFα superfamily (Table 4) (120). 
Current guidelines recommend to start pharmaceutical interventions early for tradi-
tional CVD risk factors. However, since the exact contribution of the classical CVD risk 
factors to the development of CVD in RA is still unclear and specific RA-related evidence 
for initiating CVD risk management is lacking, we feel that more evidence on the benefi-
cial effect of early and aggressive treatment of traditional CVD risk factors is necessary 
before starting widespread primary prevention. Nevertheless, much improvement may 
already be achieved with routine blood pressure monitoring and adequate treatment of 
existing hypertension using general guidelines for hypertension. 
Although the incidence of both arterial and venous thrombo-embolism is increased in 
RA (121, 122), the use of anti-platelet therapy in RA to decrease CVD risk has not been 
investigated. The concomitant use of NSAIDs might be a complicating factor, since some 
diminish the effect of aspirin, while others have significant anti-platelet effects (123). Fur-
ther studies are needed to clarify the role and safety of anti-platelet therapy in RA patients.
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Table 4. An overview of major studies, which investigated the relation of RA and non-RA medication on 
atherosclerosis in RA.
Drugs Evidence for its association with 
atherosclerosis in RA (Studies in both 
humans and animals)
Biological mechanism
NSAIDs Meta-analysis of human studies: higher risk 
of CVD. Differences between different NSAIDs 
(91) 
Animal studies not available
Not fully understood. Inhibition of COX-
2 is believed to play a role (92, 93) 
Hydroxychloroquine Case-control study: Reduced cardiovascular 
risk (132)
Animal studies not available
Improvement of dyslipidemia has been 
proposed.
Methotrexate Several studies (case control, cohort): 
cardiovascular risk reduction (8, 132), but no 
reduction has also been described (135) 
Animal studies not available
Potentially due to its anti-inflammatory 
properties, but it may also be drug 
specific.
Anti-TNFα Several case-control studies: cardiovascular 
risk reduction (130, 132) 
Animal studies not available
Anti-inflammatory effects
Improvement of endothelial function
Rituximab Conflicting data; small groups
Human: improvement of arterial stiffness as 
well as no improvement has been described. 
However, most data suggest a decrease of 
atherosclerosis progression (140-142)
Animal studies not available
Improvement of lipid profile and 
endothelial function has been 
suggested.
ACE-I/AT2 
antagonists
Small randomized trial: cardiovascular risk 
reduction (120, 152) ‘
Animal study (153) 
Improvement of endothelial function
Dose dependent depression of TNFα
Statins Randomized trial: Cardiovascular risk 
reduction (109) 
Animal study (154)
Reduction of LDL-C, which is 
comparable to the reduction in non-RA 
patients.
Improvement of endothelial function. 
Mild anti-inflammatory effects. 
Anti-inflammatory effects
Fibrates Small pilot cohort study (155)
Animal studies not available
Decrease in CRP and IL-6
Decrease of TC and TG, increase of 
HDL-C
PUFA’s Meta-analysis in humans: a possible reduction 
in cardiovascular risk
Animal study: preventive against 
atherosclerosis (156, 157)
Decrease of NSAID use.
Less necrosis and collagen in the 
atherosclerotic plaque. Reduction of 
IL-10.
Anti-inflammatory properties
Fishoil Small cohort study: Reduced cardiovascular 
risk
Animal studies not available
Several mechanisms such as increase 
of n-3- fatty acids and decrease of 
n-6-fatty acids, but also a concomitant 
decrease in NSAID use (158)
NSAIDs = non-steroidal anti-inflammatory drugs; COX = cyclo-oxygenase; ACE-I = angiotensin converting 
enzyme inhibitor; AT2 = angiotensin 2; TC = total cholesterol; TG = triglycerides; PUFA = poly-unsaturated 
fatty acids; IL = interleukin; TNF = tumour necrosis factor
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The influence of DMARD therapy on lipid levels
Intensive DMARD therapy results in a better suppression of disease activity and therefore 
a suppression of the general inflammatory state. There is a complex interplay between 
traditional CVD risk factors and the risk caused by the inflammatory burden at the lipid 
level. Since DMARD therapy decreases inflammation it is not surprising that dyslipid-
emia may improve upon DMARD therapy. Hydroxychloroquine decreases LDL-C and 
total cholesterol levels (124). Long term treatment with TNFα inhibitors is significantly 
associated with increased HDL-C, total cholesterol and triglyceride levels and may be 
associated with a decreased apo B to apo A-I ratio (125-127), but there is no significant 
change in LDL-C and the atherogenic index (125, 126). Recently Navarro-Milán et al. 
showed an increase in HDL-C, LDL-C and total cholesterol shortly after treatment initia-
tion with methotrexate alone or in combination with etanercept or hydroxychloroquine 
and sulphasalazine (128). Interestingly, increased HDL-C levels were only observed in RA 
patients who responded to DMARD therapy (93% methotrexate, 14% other DMARDs) in 
contrast to non-responders who did not show a beneficial effect on HDL-C levels (129). 
This illustrates that change in lipid levels upon DMARD therapy correlates with disease 
activity. 
DMARD treatment and cardiovascular disease
Over the last years a growing number of studies on CVD risk reduction by different 
individual DMARDs has been published. Numerous studies have described a beneficial 
effect on CVD in RA by methotrexate (MTX) and biologicals, showing a decrease in 
cardiovascular morbidity and mortality (Table 4) (8, 130-132). However, the reduction in 
CVD by TNFα inhibitors is not as consistently seen as with studies of MTX. Improvement 
of subclinical and clinical atherosclerosis by DMARDs has been observed as well. Treat-
ment with MTX, during one year, resulted in a reduction in cIMT, reflecting a reduction in 
atherosclerosis (133). A systematic review concerning MTX and CVD in RA showed strong 
evidence that the use of MTX was associated with reduced cardiovascular morbidity 
and mortality (134). However, a recent cohort study did not confirm this finding (135). It 
should be noted that all 10.156 included RA patients in this study were receiving various 
DMARDs. It is not clear whether lowering the CVD risk by MTX is caused by reducing 
RA disease activity or by a reduced inflammation in general. Therefore, it remains to 
be shown whether MTX will lower cardiovascular event rates in non-RA patients. The 
first trial addressing this question is the ongoing Cardiovascular Inflammation Reduc-
tion Trial (CIRT) (www.clinicaltrials.gov; trial number NCT01594333). Because of the 
important role of TNFα in the development of atherosclerosis, most studies investigated 
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the effects of anti-TNFα therapy in relation to CVD (136). The addition of infliximab to 
MTX for 12 weeks resulted in improved FMD (137). One-year treatment with anti-TNFα 
therapy in patients with inflammatory arthropathies including RA resulted in reduced 
arterial stiffness and less progression in cIMT when compared to RA patients not receiv-
ing anti-TNFα therapy (131, 138). A longitudinal cohort study reported that RA patients 
using anti-TNFα showed a reduction in cardiovascular events compared to RA patients 
using other DMARDs than anti-TNFα (HR 0.39; 95% CI 0.19-0.82) (135). A recent system-
atic review showed that in most studies, anti-TNFα therapy reduced the likelihood of 
CVD in RA (139). The balance of evidence suggests that TNF-α antagonists have a benefi-
cial effect on cardiovascular risk (Table 4). However, larger and more robust studies are 
warranted to confirm recent findings. The effects of anti B-cell therapy, i.e. Rituximab, 
remains inconclusive (140, 141). Several studies showed improvement of endothelial 
function after treatment with rituximab (140, 142, 143), but others did not show (141). 
These contradictory results may be explained by the role of B-cells in the development 
of atherosclerosis since immature B-lymphocytes (B1) seem to be protective against ath-
erosclerosis (144) and mature B-lymphocytes (B2) may aggravate atherosclerosis (145). 
Conclusion
Current knowledge suggests that RA patients need to be routinely screened for CVD 
risk factors. RA patients will benefit from routine cardiovascular screening since there is 
much evidence of underdiagnosis and undertreatment of traditional CVD risk factors in 
RA. The first steps to improve CVD risk assessment in RA are being taken in national as 
well as international guidelines with the adaptation of traditional risk assessment tools 
such as the SCORE or Framingham risk score. Risk stratification may be further improved 
by carotid plaque detection with ultrasound in all RA patients. Randomized controlled 
trials are needed to evaluate the effects of the suggested strict cardiovascular treatment 
versus current practise. It would be interesting to investigate treatment of RA patients 
with lipid lowering drugs to the same extent as current practise in patients with diabetes 
mellitus of CVD. Finally, a validated CVD risk assessment tool for RA should be developed. 
Considering current evidence a routinely referral of RA patients to a vascular outpatient 
clinic for cardiovascular screening and treatment seems advisable.
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Abstract
Objective: To investigate the prevalence of underdiagnosis and undertreatment of 
traditional cardiovascular risk factors in RA patients.
Methods: RA patients ≤70 years of age without CVD or diabetes mellitus were included. 
Systolic blood pressure (sBP) and a fasting lipid profile were measured. The 10-year CVD 
risk was estimated using the Dutch Cardiovascular Risk Management (CVRM) guideline 
and EULAR modifications of the SCORE Tables.
Results: 327 Patients were included (female gender: 68%). Age (mean±SD) was 53±11 
years. Median disease duration was 7 years (IQR: 2-14 years). According to the CVRM 
guideline, 52% patients had a CVD risk ≥20% and according to the EULAR guideline 18%. 
LDL-C ≥2.5mmol/l was found in >80% of the patients with a CVD risk ≥10% estimated 
by both the CVRM and EULAR guidelines. 32-42% of the patients with a CVD risk ≥10% 
had a sBP >140mmHg, depending on the risk model used. Statins were used in 6% and 
antihypertensives in 23-25% of whom 50-86% did not reach the recommended treat-
ment targets. 
Conclusion: Regardless of the adapted risk assessment model used, untreated hyper-
tension and hypercholesterolemia were frequently found in RA patients with increased 
CVD risk. Treatment of these cardiovascular risk factors deserves more attention in RA.
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Introduction
The evidence on the increased risk for cardiovascular disease (CVD) in rheumatoid 
arthritis (RA) has accumulated during the last two decades (1-3). It has been sug-
gested that the prevalence of CVD in patients with RA is as high as in patients with 
type 2 diabetes mellitus (T2DM) (1, 4). Traditional cardiovascular risk factors, such as 
hypercholesterolemia and hypertension, and RA specific risk factors, such as RA disease 
activity, erythrocyte sedimentation rates and C-reactive protein levels may play a role 
in the overall CVD risk of RA patients (5-8). The importance of traditional CVD risk fac-
tors has been strengthened by recent national and international recommendations. 
However, because of the excess CVD risk, the traditional risk assessment algorithms (the 
SCORE [Systemic COronary Risk Evaluation] or Framingham Risk Score Tables) do not 
seem valid. Therefore, adaptations of these risk models were suggested by the European 
League Against Rheumatism (EULAR) in 2010 specifically aimed at CVD risk management 
in RA and other forms of inflammatory arthritis (9). These recommendations include a 
multiplication of the measured CVD risk as assessed by the SCORE or the Framingham 
Risk Score Tables by a factor of 1.5 for patients with RA and extra risk criteria as de-
scribed in Table 1 (9). The 2011 Dutch guideline for CVD risk management (CVRM) also 
proposes modifications of the standard risk assessment tool for RA patients (10). The 
Dutch CVRM guideline recommends the addition of 15 years to the age of RA patients 
when establishing their risk according to the SCORE Tables (Table 1). These modifica-
tions of the original risk stratification models have a large impact on current care, since 
the number of patients eligible for treatment of hypertension and hypercholesterolemia 
may increase substantially. In this study, we evaluated the degree of underdiagnosis and 
undertreatment of hypertension and hypercholesterolemia in RA patients at inclusion in 
an open label intervention trial treating CVD risk factors (the FRANCIS study) when two 
different risk assessment models were applied.
Table 1. National and international guidelines for CVD risk assessment in RA patients.
Adaptations to CVD risk assessment according to SCORE
EULAR guideline (2010) CVD risk* x 1.5 if at least two of following characteristics are 
present:
- > 10 years RA disease duration 
- RF and/or anti-CCP positivity 
- severe extra articular disease 
Dutch guideline for CVD risk management (2011) Age +15 years for all RA patients**
* According to SCORE and/or Framingham
** For assessment of CVD risk according to SCORE 
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Material and Methods
Study design
Cross-sectional study in RA patients investigating the prevalence and treatment of 
hypercholesterolemia and hypertension. Differences between the performance of dif-
ferent risk assessment models were explored.
Data collection
The data for this study were part of the FRANCIS (Franciscus Rheumatoid Arthritis and 
Cardiovascular Intervention Study) study. The FRANCIS study is an open label random-
ized clinical trial in which RA patients younger than 70 years old and without current CVD 
or T2DM were either randomized to intensive treatment with pre-specified targets and 
recommendations on lifestyle changes or were referred to their general practitioner for 
treatment of these risk factors (Dutch Trial Register NTR3873; ABR no. NL32669101.10). 
All the data presented here are baseline data, which were collected at study entry before 
randomization.
CVD was defined as a prior myocardial infarction, cerebrovascular event, amputation 
due to peripheral artery disease, intermittent claudication, percutaneous transluminal 
coronary angioplasty (PTCA) or coronary artery bypass graft (CABG). T2DM was defined 
as fasting glucose >7.0 mmol/l. All patients at inclusion were routinely screened for tra-
ditional cardiovascular risk factors at the Diabetes and Vascular Center, Sint Franciscus 
Gasthuis, Rotterdam, the Netherlands. 
The Institutional Review Board of the Sint Franciscus Gasthuis in Rotterdam and the 
regional independent medical ethics committee, Maasstad Hospital, Rotterdam, ap-
proved the study. The study was conducted according to the Declaration of Helsinki. 
All participants gave written informed consent. The FRANCIS study is registered in the 
Dutch Trial Register (NTR3873).
Definition of hypertension and hypercholesterolemia
Hypertension was defined as a systolic blood pressure of >140mmHg and/or the use of 
antihypertensive drugs. Hypercholesterolemia was defined a LDL-C >2.5mmol/l and/or 
the use of lipid lowering drugs. 
Underdiagnosis was defined as a systolic blood pressure or LDL-C above the above 
mentioned targets in patients with a CVD risk ≥10%. Undertreatment was established 
when a specific patient was already treated for hypertension and/or hypercholesterol-
emia without reaching the treatment targets.
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Cardiovascular risk assessment
The 10-year cardiovascular risk was assessed using the SCORE Tables following the modi-
fied 2010 EULAR recommendations and the 2011 Dutch CVRM guideline (Table 1) (9, 10).
Rheumatoid arthritis disease activity
Rheumatoid arthritis disease activity was assessed using the Disease Activity Score with 
28 joints counted (DAS28). This score included swollen joint count (28), tender joint 
count (28), VAS score (scale 0-100) indicating pain and discomfort due to RA, and the 
level of C-reactive protein (CRP). 
Laboratory measurements
A standardized set of measurements was performed in each subject. Blood samples 
were drawn after an overnight fast. Laboratory parameters were determined at the 
Department of Clinical Chemistry, Sint Franciscus Gasthuis, Rotterdam, the Netherlands. 
Renal and liver function tests as well as glucose, CRP, total cholesterol, HDL-C and tri-
glycerides (TG) were measured using Synchrom LX or DxC analyzers (Beckman Coulter, 
Anaheim CA, USA). LDL-C was calculated using the Friedewald formula if TG were below 
4.00 mmol/l. Apolipoprotein (apo) AI and apo B were determined by rate nephelometry 
using IMMAGE with commercially available kits (Beckman Coulter).
Statistics
Data are given as mean ± standard deviation (SD) in the text and Tables unless stated 
otherwise. Differences between risk assessment models were determined using the 
paired t-test. P-values below 0.05 (two sided) were considered statistically significant. 
All statistical analyses were performed using PASW statistics version 18.0 (IBM SPSS 
Statistics, New York, United States). 
Results
General Characteristics 
Of the 332 patients who were referred to the outpatient clinic, 5 were excluded because 
of previously undiagnosed T2DM. 223 Of the 327 included RA patients were female 
(68%). The mean age was 53 ± 11 years and the median RA disease duration was 7 years 
(IQR 2-14 years). The median DAS28CRP was 2.1 (IQR 1.6-3.0). Disease remission (DAS-
28CRP <2.6) was achieved in 187 patients (57.3%), 41 (12.5%) had low disease activity 
(DAS28CRP 2.6-3.1), 66 (20.2%) moderate disease activity (DAS28CRP 3.1-5.1) and 27 
(8.3%) had high disease activity (DAS28CRP >5.1). DAS28CRP data were missing in six 
patients at inclusion. The general characteristics are shown in Table 2. 
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Cardiovascular risk assessment
The mean CVD risk according to the SCORE model was 8%. According to the standard 
SCORE model 228 patients (70%) had a CVD risk of 0-9%, 58 patients (18%) had a CVD 
risk of 10-19% and 39 (12%) had a CVD risk of ≥20%. According to the EULAR guidelines 
the mean CVD risk increased to 11%. The number of patients with a CVD risk of 0-9% 
decreased to 203 (61%), 62 patients (20%) had a CVD risk of 10-19% and 60 patients 
(18%) had a CVD risk of ≥20%. According to the Dutch CVRM guideline, the mean CVD 
risk increased to 21%. The number of patients with a CVD risk of 0-9% decreased to 104 
(32%), 50 patients (16%) had a CVD risk of 10-19% and the number of patients with a 
CVD risk of ≥20% increased to 171 patients (52%) (Figure 1). The estimated CVD risk by 
the three models was significantly different (P<0.001).
Table 2. General characteristics and fasting laboratory measurements.
N= 327
Mean ± SD
Female (n,%) 223 (68%)
Age (yrs) 53 ± 11
Body mass index (kg/m2) 26.5 ± 4.5
Waist circumference (cm) 94 ± 14
Current smoker (n,%) 60 (19%)
Systolic blood pressure (mmHg) 132 ± 19
Diastolic blood pressure (mmHg) 79 ± 10
Total cholesterol (mmol/l) 5.4 ± 1.1
LDL-C (mmol/l) 3.4 ± 0.9
HDL-C (mmol/l) 1.47 ± 0.41
Triglycerides (mmol/l) median (IQR) 1.05 (0.73-1.51)
Apolipoprotein AI (g/L) 1.69 ± 0.37
Apolipoprotein B (g/L) 1.00 ± 0.26
Fasting glucose (mmol/L) 5.46 ± 0.56
HbA1C (mmol/mol) 35 ± 4.4
RA disease duration (yrs) median (IQR) 7 (2-14)
Rheumafactor positive (n,%) 198 (60%)
Anti CCP positive (n,%)* 181 (66%)
Erosive disease (n,%)** 126 (44%)
DAS28CRP median (IQR) 2.1 (1.6-3.0)
Statin use (n,%) 15 (4.6%)
Anti-hypertensive use (n,%) 56 (17.1%)
* Anti-CCP levels were available in 274 patients 
** Status of erosive disease was available in 284 patients
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Underdiagnosis and undertreatment of hypertension and hypercholesterolemia 
When using the Dutch CVRM recommendations, 221 patients had a CVD risk score ≥10% 
and therefore, had an indication for treatment of their cardiovascular risk. Of those 221 
patients, 72 (32%) had a systolic blood pressure >140 mmHg and 185 (84%) had anLDL-C 
>2.5 mmol/l. Considering all patients with a CVD risk of ≥10%, only 51 patients (23%) 
were treated with antihypertensives of whom 28 (50%) still had a systolic blood pressure 
>140mmHg. When analyzing the 14 patients already treated with statins, 12 (86%) did 
not reach the treatment target (Table 3). 
With respect to the 171 patients with a CVD risk of ≥20%, 9 (5%) and 43 (25%) 
patients were treated with antihypertensives and/or statins, respectively (Table 3). 
Despite treatment, 24 (56%) out of the 43 patients treated with antihypertensives still 
had a systolic blood pressure >140 mmHg. In addition, six patients (67%) out of the 
nine patients treated with statins still had hypercholesterolemia in the highest CVD 
risk group.
When applying the EULAR guideline for CVD risk assessment, 122 (38%) patients 
had a CVD risk of ≥10%. Fifty-one of those patients (42%) had a systolic blood pres-
sure >140mmHg and 102 (84%) had an LDL-C >2.5 mmol/l. 31 Patients (25%) used 
antihypertensives and of those, 18 (58%) did not reach the treatment target (Table 3). 
Only seven out of those 122 patients used statins and six (86%) did not reach the target. 
Considering the 60 patients with a CVD risk ≥20% according to the EULAR guideline, 
only 1 (2%) used a statin but without reaching the treatment target. Antihypertensives 
were prescribed to 14 patients (23%) and 7 (50%) still had a systolic blood pressure of 
>140mmHg. There was no significant correlation between systolic blood pressure and 
CRP (Pearson’s r=0.052; p=0.353) although there was a trend with ESR (r=0.106; p=0.056). 
A statistical significant correlation between systolic blood pressure and DAS28 levels 
was found (r=0.128; p=0.027).
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Figure 1. Ten-year cardiovascular risk 
stratification according to different CVD 
risk assessment tools. Abbreviations: 
SCORE = Systemic Coronary Risk Evalu-
ation, CVRM = the Dutch guideline for 
Cardiovascular Risk Management, EU-
LAR = European League Against Rheu-
matism.
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Discussion 
This study shows that traditional cardiovascular risk factors such as hypertension and 
hypercholesterolemia are highly prevalent in RA patients following current guidelines, 
indicating significant underdiagnosis. Furthermore, the majority of RA patients already 
treated for hypertension and hypercholesterolemia did not reach the advised treatment 
targets for systolic blood pressure and/or LDL-C. These results are in line with previous 
studies reporting undertreatment of hypertension and hyperlipidemia in RA patients 
(11, 12). Some experts may argue that the cardiovascular risk in RA is so high that these 
patients may be eligible for preventive measures at an earlier stage. An option could be 
to define targets for risk factors in these patients and apply a treat-to-target approach, 
independently from the risk calculated by the above mentioned algorithms. However, at 
this stage there are no clinical trials to support such an approach. Furthermore, it is not 
currently known to what extent traditional CVD risk factors in the general population 
are directly applicable to RA patients. We therefore chose to apply here the SCORE risk 
Tables and the Dutch Risk Score algorithm for RA patients to calculate the overall risk. 
The number of patient with hypercholesterolemia in our study is markedly higher 
than previously reported and this may be the result of application of the current CVRM 
guideline. The consequence of this guideline, is that the number of patients eligible for 
treatment increases. Moreover, the treatment target for LDL-C is lower than in previous 
recommendations. This situation is similar to primary prevention in the general popula-
tion where undertreatment of 50% of the investigated patients has been reported (12, 
13). Even in the case of secondary prevention large numbers of patients do not reach 
treatment targets for blood pressure and lipid levels (14, 15). 
Although the ongoing inflammation is directly related to arterial wall stiffness and 
endothelial dysfunction (6), the role of inflammation on blood pressure is still under 
debate. In this study, we found a statistical significant association between DAS28 
Table 3. Risk factors and medication use in different CVD risk categories according to the CVRM and EULAR 
guidelines.
Estimated CVD risk according to 
CVRM guideline
Estimated CVD risk according to 
EULAR guideline
10-19%
(n=50)
≥20%
(n=171)
10-19%
(n=62)
≥20%
(n=60)
LDL-C >2.5 mmol/l (n,%) 37 (74%) 148 (87%) 53 (86%) 49 (88%)
sBP >140mmHg (n,%) 7 (14%) 65 (38%) 25 (40%) 26 (43%)
Statin use (n,%) 5 (10%)  9 (5%)  6 (10%) 1 (2%)
Anti-hypertensive use (n,%) 8 (16%) 43 (25%) 17 (27%) 14 (23%)
Abbreviations: sBP = systolic blood pressure, CVRM = Cardiovascular Risk Management, EULAR = European 
League Against Rheumatism
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and systolic blood pressure, however the low correlation coefficient implies that this 
influence is probably not clinically significant. We did not find a significant association 
between other markers of inflammation (ESR, CRP) and systolic blood pressure. This is in 
line with data reported by Manavathongchai et al. (16). 
The exact contribution of traditional CVD risk factors in the development of CVD in 
RA remains unclear since their presence alone does not seem to fully explain the excess 
CVD risk in these patients (5, 17). However, currently there is no reason to believe that 
the traditional CVD risk factors would not be associated to CVD risk in RA, similarly to 
the general population (5, 7). In order to minimize underdiagnosis and undertreatment 
it is important to identify the patients at risk. At present RA specific CVD risk assessment 
tools are not available and the existing algorithms for the general population may not 
be valid in RA. The differences in CVD risk in both suggested models for RA patients 
(CVRM and EULAR) underscore the level of uncertainty when predicting the CVD risk of 
an individual RA patient. Also, the scientific basis for the suggested adaptations of the 
CVRM and EULAR guidelines is limited. Inclusion of the factor “RA disease duration of 
>10 years” as recommended in the EULAR guideline (9), is debatable because the risk for 
cardiovascular morbidity and mortality is already increased shortly after the diagnosis of 
RA, which underscores the importance of early detection and intervention in relation to 
CVD risk factors (18, 19). Recent studies showed that the EULAR adaptations do not offer 
a better risk prediction in RA compared to the original SCORE system (20). The addition 
of 15 years of age in the Dutch guideline for cardiovascular risk management is based on 
data in T2DM patients and it is unclear whether this can be extrapolated to RA patients 
(21). To date no studies have validated the predictive value of the adaptations according 
to the CVRM guideline. The modifications of the existing SCORE (22) and Framingham 
(23) risk assessment by the EULAR and Dutch CVRM guidelines do not, therefore offer a 
real solution and there is need for an RA specific risk assessment tool (24). A recent study 
by Arts et al. investigated the predictive value of different adaptations to the original 
SCORE risk model. The authors added RA specific risk factors to the algorithm (i.e. DAS28, 
CRP, swollen joint count, Health Assessment Questionnaire (HAQ)) and found that these 
changes did not show sufficient improvement in risk prediction of future CVD to serve 
as an appropriate alternative to the original SCORE model (25). 
Although many questions regarding the best risk assessment model remain, it is 
important that both, patients and physicians are aware of the increased CVD risk associ-
ated with RA and that known CVD risk factors are being treated. More routine screening 
and more strict adherence to treatment targets are necessary in RA patients, especially 
since statin treatment has shown to improve lipid levels (27,28) and treatment with 
ACE-inhibitors improves vascular function in RA patients (26-28). However, it must be 
noted that these studies used surrogate endpoints. Randomized clinical trials show-
ing improved survival in RA by treating cardiovascular risk factors are still lacking. We 
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believe that in the meantime, strict cardiovascular control in RA is warranted due to the 
well established elevated cardiovascular risk. Additionally, since inflammation plays a 
key role in the development of atherosclerosis (29), a tight control of RA disease activity 
may also be very important in order to lower the CVD risk.
A risk assessment tool helps to identify patients at risk and offers guidance to physi-
cians. In view of the limited value in RA patients of the original SCORE model and the 
modified EULAR model, the modified CVRM model may be an alternative. We have shown 
that the modification according to the CVRM guideline results in a markedly higher CVD 
risk compared to the original SCORE and the EULAR modifications. Whether this high 
increase in risk is valid remains to be seen. The CVRM modification (adding 15 years to 
the age of the patient) is easily applicable and may facilitate the use in daily practice. For 
general practitioners, information necessary to apply the EULAR recommendation (i.e. 
rheumatoid factor of anti-CCP positivity, disease duration and extra-articular disease) is 
not always available. Since patients with RA not always visit their general practitioner 
regularly, rheumatologists also have a responsibility to identify patients at risk. In order 
to unify risk assessment it is desirable that both general practitioners and rheuma-
tologists use the same risk model. As stated above, the modified score according to the 
CVRM guideline may be helpful. When applying the modified SCORE model, patients 
with a CVD risk ≥20% should be advised treatment. This can be carried out either by 
the patient’s general practitioner, in which case increased awareness of the increased 
CVD risk in RA amongst general practitioners is necessary alternatively, screening and 
treatment could take place in a specialized vascular outpatient clinic. In our study, the 
majority of RA patients who were already treated for hypertension and/or hypercholes-
terolemia did not reach the recommended treatment targets. Therefore, treatment and 
follow-up need to be intensified. In patients with a CVD risk of 10%-19% according to the 
modified SCORE, treatment with lipid lowering drugs and/or antihypertensives should 
be weighed individually. Lifestyle interventions such as regular exercise, weight loss and 
smoking cessation should always be given.
In conclusion, hypertension and hypercholesterolemia are not being identified opti-
mally and, when identified, not adequately treated. Although the validity of the adapted 
risk score systems in RA is debatable, it remains important to screen for and to treat 
cardiovascular risk factors. The CVRM may at this point be the best and most practical 
risk assessment tool. The FRANCIS study will reveal whether it is effective to screen and 
treat RA patients following a tight control regimen for traditional CVD risk factors. Await-
ing these results as well as an RA specific risk assessment tool, physicians need to be 
more aware of screening and treatment of CVD risk factors in RA patients.
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Abstract
Objective: Patients with rheumatoid arthritis (RA) have a high cardiovascular disease 
(CVD) risk. Recent national and international guidelines suggest strict treatment of CVD 
risk factors in RA. The aim of this study is to evaluate the self-reported adherence to 
cardiovascular prevention strategies in patients with RA.
Methods: RA patients visiting an outpatient clinic for strict CVD risk management 
received a validated questionnaire in order to evaluate adherence to cardiovascular pre-
vention strategies. Strict treatment targets were defined and lifestyle recommendations 
were given following a pre-specified protocol. CVD risk was assessed using the SCORE 
algorithm.
Results: In total, 111 questionnaires were returned (response rate of 82%). A high 10-
year CVD risk (≥20%) was present in 53%, but only 3% thought they had an increased 
CVD risk. 53% Reported to “follow the doctors’ suggestions exactly” and 75% reported 
to find it “easy to follow the suggestions”. From the 69% of patients who were prescribed 
lipid and/or blood pressure lowering drugs, 90% reported to take all prescribed tablets. 
The advice to follow a diet was given to 42% of whom 68% said to follow the advised 
diet. Physical exercise was advised to 67% of whom 62% said to perform specific physi-
cal exercise on 3 days or more per week. The adherence to lifestyle recommendations 
was not significantly different across CVD risk groups. 
Conclusion: RA patients tend to underestimate their CVD risk. The self-reported adher-
ence of RA patients to CVD risk management was high concerning pharmaceutical 
interventions and moderate in the case of lifestyle interventions.
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Introduction
Patients with rheumatoid arthritis (RA) have an increased cardiovascular disease (CVD) 
risk. The exact mechanism behind this increased risk is still unclear. Since atherosclerosis 
is an inflammatory disease, the increased inflammatory state of RA patients may explain, 
at least in part, the increased CVD risk (1-4). Several studies showed that traditional 
CVD risk factors behave differently in RA patients compared to the general population, 
nevertheless it is a common believe that they remain important in the development of 
atherosclerosis in RA patients (4). 
There is evidence of underdiagnosis and undertreatment of traditional CVD risk fac-
tors in RA patients both in primary prevention (5-7) and in secondary prevention (8). 
Recent cardiovascular risk management guidelines included specific adaptations for RA 
patients for the calculation of their CVD risk (9, 10). For instance, the Dutch cardiovas-
cular risk management (CVRM) guideline states that 15 years should be added to the 
age of RA patients, when assessing the CVD risk according to the score algorithm (10). 
Awareness of this increased risk among physicians is growing and with that, the screen-
ing for and treatment of cardiovascular risk factors in RA patients. 
Adherence to cardiovascular prevention regimens is generally low (45-66%), espe-
cially in the case of primary prevention (11). This lack of adherence to recommendations 
results in an increased risk of CVD due to suboptimal treatment (12-14). In order to be 
able to assess the effect of primary cardiovascular prevention it is necessary be informed 
on the adherence to given recommendations and treatments. The adherence to cardio-
vascular prevention strategies in RA patients has not yet been investigated. Therefore, 
the aim of this study was to investigate CVD risk awareness and adherence to lifestyle 
and pharmaceutical interventions for primary cardiovascular prevention in RA patients. 
Materials and methods
Subjects
RA patients visiting the Diabetes and Vascular Medicine outpatient clinic, St. Franciscus 
Hospital, Rotterdam, the Netherlands, who participated in the FRANCIS study (Franciscus 
Rheumatoid Arthritis aNd Cardiovascular Intervention Study) (the Dutch trial register 
number NTR3873) received a questionnaire in order to evaluate adherence to primary 
cardiovascular prevention strategies.
The FRANCIS study is an open label randomised intervention trial. RA patients up to 70 
years old and without type 2 diabetes mellitus or cardiovascular were eligible to partici-
pate. The age limit of 70 was chosen in order to achieve a more favourable cardiovascular 
condition at inclusion and to increase the probability for a long-term follow up. CVD was 
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defined as a previous myocardial infarction, PTCA or CABG, cerebrovascular accident or 
transient ischemic attack, severe intermittent claudication and/or amputation due to 
arterial vascular disease. Patients were recruited by their rheumatologist and referred to 
the outpatient clinic for Diabetes and Vascular Medicine. Since this study was initiated 
before the publication of the Dutch CVRM, that suggests an adaptation of the SCORE risk 
assessment for RA patients, at inclusion the unadjusted risk assessment was used. Patients 
with a cardiovascular risk score of <20% were randomized 1:1 into two groups; usual care 
versus tight control. Patients with a risk score >20% received tight control according to 
the protocol and were followed in a separate cohort. All included patients visited the 
outpatient clinic every six months. At each visit standard laboratory tests and physical 
examination were performed. Patients allocated to the usual care arm were referred to 
their general practitioner for treatment of cardiovascular risk factors (i.e. high blood pres-
sure, dyslipidaemia, diabetes, obesity) with detailed information. Patients allocated to the 
tight control arm or the high risk cohort were treated according to a structured CVD risk 
management program offered by a multidisciplinary team comprising a vascular special-
ist, a dietician and specialized nurses for vascular and RA care. Lifestyle recommendations 
and pharmaceutical therapy to reduce CVD risk were initiated according to a strict pre-
specified protocol. Furthermore, smoking habit was addressed repeatedly and patients 
were offered a visit to the outpatient clinic for smoking cessation.
In total 706 patients were eligible for participation in the FRANCIS trial, of whom 324 
consented to participation. Of them 316 patients had a CVD <20% and were random-
ized; the remaining 8 patients entered the high CVD risk group. All patients who had 
been included in the tight control arm or the high-risk cohort and who had been fol-
lowed for at least 6 months received a questionnaire concerning adherence to the given 
interventions. Patients were reminded once by telephone in case of non-response. 
Questionnaires
The questionnaire used in this study (Appendix) was a combination of the Medical 
Outcome Study Measures of Patient Adherence (MOS) (15) and a previous version of the 
current disease specific Summary of Diabetes Self Care Activities (SDSCA) questionnaire 
(16). Both original questionnaires were validated English questionnaires and our version 
was translated into Dutch through back translation by a native English speaker. 
In the MOS questionnaire patients were given 5 general statements on adherence and 
they were provided with 6 answer categories ranging from none of the time to all of the 
time.
In the SDSCA questionnaire adherence to specific advices a patient may have received 
were asked. Answer categories regarding diet and exercise varied between percentages 
(0%, 25%, 50%, 75%, 100%) and number of days per week (1-7 days). For medication 
intake there are 4 answer categories ranging from “all of them” to “none of them”. This 
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differs from the current version of the SDSCA questionnaire where all questions are 
changed in order to uniform all answer categories into the total number of days per 
week. In addition, we removed questions on glucose monitoring and foot care since 
we considered them irrelevant to this RA patient group since the presence of diabetes 
mellitus was an exclusion criterion. Questions regarding oral glucose lowering drugs 
and insulin were replaced by medication in general and RA medication. 
Furthermore, a non-validated question about cardiovascular risk awareness was 
added. (i.e. How high do you think your risk of getting a myocardial infarction is? “High”, 
“not more than average”, “low”, “almost zero”).
Laboratory measurements
A standardized set of measurements was performed in each subject. Blood samples 
were drawn after an overnight fast. Laboratory parameters were determined at the 
Department of Clinical Chemistry, Sint Franciscus Gasthuis, Rotterdam, the Netherlands. 
Glucose, C-reactive protein, total cholesterol, HDL-C and triglycerides (TG) were mea-
sured using  LX-20 or DxC analysers (Beckman Coulter, Anaheim CA, USA). LDL-C was 
calculated using the Friedewald formula if TG were below 4.00 mmol/l. The erythrocyte 
sedimentation rate was measured using an Alifax Test-1TH analyser (Beckman Coulter, 
Anaheim CA, USA)
Disease activity
Rheumatoid arthritis Disease Activity Score (DAS28) was calculated with erythrocyte 
sedimentation rate and the following 3 variables: swollen joint count (28), tender joint 
count (28) and VAS (scale 0-100). 
Statistical analysis
In order to compare adherence to general statements in different groups based on their 
CVD risk, sumscores per patient were calculated. In total 5 general statements were 
given. Each statement had 6 answer categories ranging from ‘none of the time’ to ‘all of 
the time’. The answer ‘all of the time’ was given 0 points and the statement ‘none of the 
time’ 5 points. Negative phrased statements were scored in reverse. A higher sumscore 
indicates poorer adherence. A patient’s sumscore was the total number of points allot-
ted according to their answers of these five statements. Sumscores were only calculated 
if 4 or more statements were answered. 
The actual CVD risk was calculated using the adjusted SCORE algorithm, following 
the recommendation of the 2011 CVRM guideline (9). This results in a higher CVD risk 
compared to the calculated risk using the unadjusted SCORE algorithm as we used at 
inclusion. Therefore some patients have a CVD risk of >20% who were initially included 
with a lower CVD risk.
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Data are given as mean ± standard deviation (SD) unless stated otherwise. Differences 
between groups were determined using the unpaired Student’s t-test, Chi-square test or 
ANOVA, where appropriate. In the case of skewed variables (DAS28, TG), non-parametric 
tests (Mann Whitney U test or Kruskal-Wallis test) were performed. All statistical analyses 
were carried out using PASW statistics version 18.0 (IBM SPSS Statistics, New York, United 
States). P-values below 0.05 (two sided) were considered statistically significant.
Results
General characteristics
Questionnaires were sent between June 2012 and November 2012. At that time 136 
patients with a minimum follow-up time of 6 months had been randomized in the tight 
control arm or enrolled in the high-risk cohort. In total, 111 (82%) returned a completed 
questionnaire. Respondents’ general characteristics are shown in Table 1. A high 10-
year CVD risk (≥ 20%) (according to the SCORE model with adaptations according to 
the Dutch CVRM guideline) was found in 60 patients (53%), but only 3 patients (3%) 
reported to think they had an increased cardiovascular risk. Most patients (n=93; 85%) 
were Dutch, highly educated (college/university: n=74; 69%) and had a relationship 
(n=82; 75%). Subjects with a high CVD risk were more often male, had a higher waist 
circumference, blood pressure, LDL-C, TG and glucose. Furthermore patients with a high 
CVD risk were more often rheumatoid factor and anti-CCP positive (Table 1).
General adherence statements
In the first part of the questionnaire patients were invited to answer 5 statements ad-
dressing patient’s general view on the given recommendations (Figure 1). The majority 
of the patients (n=74; 75%) stated to have “none of the time” or “a little of the time” a 
“hard time following the doctors’ suggestions” (Figure 1A). In total, 65 patients (69%) 
reported to “follow the doctors’ suggestions exactly” (“most of the time” to “always”) 
(Figure 1B) and only 4 patients (5%) were unable “to do what was necessary to follow 
the doctors’ treatment plans” (“most of the time” to “always”) (Figure 1C). The majority 
(71 patients; 75%) reported to find it easy to “follow their doctors’ suggestions exactly” 
(“most of the time” to “always”) (Figure 1D). Generally, over the past 4 weeks, 67 patients 
(72%) were “able to do what the doctor told them to do” (“most of the time” to “always”) 
(Figure 1E). The medium sumscore was 5 (IQR 3-7) in the group with a CVD risk <10% and 
10-19%. The group with a CVD risk ≥20% had a median sumscore of 4 (IQR 1-8), which 
was significantly lower than the other groups (p=0.03). 
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Adherence to specific recommendations
In the second part, questions regarding specific recommendations given by the doctor 
were asked. In the case of given recommendations, several questions followed address-
ing their adherence (Figure 2). All patients used RA medication and most of them (n=83; 
82%) said to take most to all of the prescribed tablets. Of the 77 patients that were 
prescribed antihypertensives and/or lipid lowering drugs 70 (90%) stated to take most 
to all of the prescribed tablets. The advice to follow a diet was given to 46 patients (42%) 
and 30 of them (68%) said to follow the recommended diet (“usually” to “always”). Of the 
patients that were advised to follow a diet 35 patients (76%) said to use fibre rich meals 
(75-100% of the meals), 37 patients (80%) used low fat meals (75-100% of the meals) and 
43 patients (94%) used low carbohydrate meals (75-100% of the meals). 
Physical exercise was advised to 72 patients (67%) and of them 38 (56%) said to follow 
the advice. In total 42 (62%) said to perform specific physical exercise on 3 days or more 
per week.
Figure 2 shows the adherence to recommendations across risk categories. Overall, 
there was no significant difference between the CVD risk groups. Patients with a CVD 
Table 1. General Characteristics.
Total
(n=111)
CVR <10%
(n=31)
CVR 10-20%
(n=20)
CVR ≥20%
(n=60)
p-value
Female (n,%) 86 (78%) 31 (100%) 16 (80%) 39 (65%) 0.001
Age (yrs) 54 ± 11 40 ± 7 54 ± 6*** 62 ± 6***,## <0.001
Smoking (n,%) 15 (14%) 3 (10%) 2 (10%) 10 (17%) 0.56
Height (cm) 170 ± 9 170 ± 10 173 ± 9 169 ± 9 0.29
Weight (kg) 76.7 ± 14.5 73.2 ± 13.7 78.6 ± 14.9 77.9 ± 14.6 0.27
Waist (cm) 94 ± 12 89 ± 13 95 ± 14 97 ± 11** 0.02
BMI (kg/m2) 26.5 ± 4.4 25.4 ± 4.0 26.3 ± 4.8 27.0± 4.4 0.21
BPs (mmHg) 135 ± 21 118 ± 12 129 ± 20* 145 ± 19***,## <0.001
TC (mmol/l) 5.4 ± 1.1 5.0 ± 1.1 5.0 ± 1.0 5.8 ± 1.1**,## 0.001
LDL-C (mmol/l) 3.3 ± 1.0 3.0 ± 0.8 3.0 ± 0.9 3.6 ± 1.0**,# 0.003
HDL-C (mmol/l) 1.53 ± 0.44 1.55 ± 0.40 1.50 ± 0.41 1.53 ± 0.47 0.91
TG (mmol/l) median (IQR) 0.97 (0.73-1.49) 0.86 (0.63-1.14) 0.87 (0.72-1.46) 1.10 (0.83-1.77) 0.036
Glucose (mmol/l) 5.5 ± 0.4 5.1 ± 0.5 5.5 ± 0.4* 5.6 ± 0.6*** <0.001
HbA1c (mmol/mol) 34.8 ± 4.8 32.7 ± 4.4 35.6 ± 3.1* 35.7 ± 5.1** 0.01
Anti-CCP + (n,%) 63 (57%) 12 (39%) 10 (50%) 41 (69%) 0.003
RF + (n,%) 64 (58%) 13 (42%) 11 (55%) 40 (67%) 0.02
Erosions (n,%) 49 (44%) 11 (36%) 11 (55%) 27 (45%) 0.61
DAS28 Median (IQR) 2.4 (1.6-3.4) 1.8 (1.1-2.6) 2.7 (2.1-4.0) 2.5 (1.7-3.0) 0.047
* P<0.05 vs. CVR <10%, ** P<0.01 vs. CVR <10%, ***P<0.001 vs. CVR <10%
# P<0.05 vs. CVR <20%, ## P<0.01 vs. CVR <20%, ###P<0.001 vs. CVR <20%
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risk of 10-19% reported a higher adherence to dietary advice compared to patients with 
higher and lower CVD risks: n=9 (100%) versus n=17 (71%) and n=4 (36%), respectively: 
p=0.018). Their cardiovascular medication use was also reported to be higher compared 
to patients with a lower and higher cardiovascular risk n=13 (100%) versus n=9 (82%) 
and n=42 (89%) respectively; p<0.001). 
I had a hard time doing what the doctor 
suggested I do… 
I followed my doctors  
suggestions exactly 
I found it easy to do the things my doctor 
suggested I do… 
Generally speaking, how often during  
the past 4 weeks were you able 
 to do what the doctor told you? 
All of the time 
Most of the time 
A good bit of the time 
Some of the time 
A little of the time 
None of the time 
A B 
I was unable to do what was necessary to 
follow my doctor's treatment plans… 
C 
E 
D 
Figure 1. Patients reports on general adherence statements. In the MOS questionnaire patients were giv-
en 5 general statements on adherence and they were provided with 6 answer categories ranging from all 
of the time to none of the time.
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Discussion
This is the first study addressing the self-reported adherence to cardiovascular risk 
strategies in RA patients. 
All patients consented to participation in the FRANCIS study, an intervention trial 
on CVD risk management in RA patients. In view of the wide trial inclusion criteria we 
adopted, selective participation appeared minimal. However, patient’s willingness of 
unwillingness to participate, may have resulted in higher adherence rates than is to 
be expected in the general unselected RA population. This selection may also be the 
reason why the proportion of smokers was relatively low and even lower than previously 
reported in the Dutch RA population (17). Despite the fact that the patient information 
leaflet of the FRANCIS study contained detailed information on the increased CVD risk 
in RA, all but three patients stated to have an average or below average risk to develop 
a myocardial infarction, indicating low CVD risk awareness.
The exact influence of treatment of traditional CVD risk factors in RA patients on 
their CVD risk is unclear, especially concerning lifestyle (1). With respect to exercise, an 
0% 20% 40% 60% 80% 100%
Followed advice to exercise*
≥ 3 Days specific exercise
Followed dietary advice**
Succesfully limited calories*
Fibre rich meals*
Low fat meals*
Low intake of sugar/sweets*
Has taken prescribed CV medication***
Has taken precribed RA medication***
Total
<10%
10-19%
>20%
Figure 2. Patient reported adherence to given recommendations provided for the respective CVD risk 
groups. In The SDSCA questionnaire adherence to specific advices a patient may have received were asked. 
* 75%-100% of the time, **usually to always, *** most of them to all of them
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individualized training program in RA has been shown to improve endothelial function 
(18). Furthermore, inactivity in RA has also been associated with increased arterial stiff-
ness (19). However, the effect on real life CVD risk is unknown. Regarding cardiovascular 
preventive medication in RA, several studies have shown a favourable effect. Statin 
treatment effectively improves lipid levels in RA patients (5, 20) and anti-hypertensive 
treatment with ACE-I and angiotensin II antagonists effectively lower blood pressure 
and improves endothelial function in RA (21-23). The response to calcium channel and 
beta-blockers is decreased in inflammatory conditions, therefore the effect of these 
antihypertensives may be attenuated in RA. Clinical data, regarding this attenuated ef-
fect, however are lacking. The on-going FRANCIS study intends to answer the question 
what the effect of tight treatment of traditional CVD risk factors RA is on CVD risk and 
subclinical atherosclerosis. 
The impression of the first part of the questionnaire, addressing adherence to given 
CVD recommendations in general, was favourable since patients stated to have a high 
adherence and not to have difficulties following given advices. There was a significant 
difference in sumscores between the risk groups, however we feel that this difference is 
not clinically significant. With sumscores ranging between 0 and 25, median scores of 5 
and 4 indicate relatively good self-reported adherence. The second part of the question-
naire, assessing adherence to specific advices, however showed more variable adher-
ences, depending on the advice questioned. Medication intake adherence for both RA 
specific and CVD preventive medication and for RA specific medication was high (82% 
and 90% respectively). These results are in line with previous studies on self-reported 
adherence to RA medication (24-26). To date, data on the adherence to primary CV 
preventive drugs in RA is absent. Despite the fact that overall adherence to secondary 
prevention is higher than adherence to primary preventive strategies, a recent report 
on adherence to secondary prevention in RA showed adherence rates of 80% (8). Previ-
ous reports on primary CV prevention in DM have shown adherence rates of 77%-80% 
(27, 28). The methods to measure adherence differs in different studies making direct 
comparisons difficult. The use of questionnaires may also lead to an overestimation of 
adherence rates. Garber et al found that questionnaires for the estimation of adherence 
to medication, show a moderate to high concordance with objective measurements of 
adherence (29). We did not establish adherence to specific medication, but measured 
general adherence to all CVD preventive medication, which included mainly antihy-
pertensives and statins, and adherence to all RA specific medication. We have to admit 
that this way to measure adherence may be inaccurate since several studies showed 
that adherence strongly depended on the type of drug (8, 25, 30). Factors related to 
adherence may be patient related (coping, physical health) or related to specific drug 
related side effects (25). The overall low RA disease activity indicates a high medication 
adherence, which is in line with the results of the questionnaire. 
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The adherence to lifestyle interventions such as exercise and diet was lower than 
adherence to medication and ranged between 49% and 94%. One of the factors for low 
physical exercise in RA may be related to the RA disease activity and/or joint deformity. 
Although overall disease activity was low, specific information on patient reported im-
pairment to exercise was not available. Surprisingly, a higher cardiovascular risk did not 
result in higher adherence. A possible explanation for this could be that most RA patients 
believed to have an average or below average CVD risk regardless their actual CVD risk. 
In order to optimize treatment of CVD risk factors in RA it is necessary to increase 
patient awareness of this increased risk and to identify factors that are correlated with 
poorer adherence. The next step would be to optimize adherence. Ways to increase 
awareness may include an active role of general practitioners in screening and treat-
ment, patient-related educational interventions with behavioural support, internet and 
mobile technologies regarding the CVD risk in RA and/or an active role for specialized 
nurses in rheumatology to inform patients.
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Association of cardiovascular 
risk factors with carotid intima 
media thickness in patients with 
rheumatoid arthritis with low 
disease activity compared to 
controls: A cross-sectional study
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Abstract
Objectives: Rheumatoid arthritis (RA) has been identified as an independent cardiovas-
cular risk factor. The importance of risk factors such as hypertension and hyperlipidemia 
in the generation of atherosclerosis in RA patients is unclear. This study analyzed clinical 
parameters associated with carotid intima media thickness (cIMT) in patients with RA.
Methods: Subjects with RA and healthy controls without RA, both without known 
cardiovascular disease, were included. Participants underwent a standard physical 
examination and laboratory measurements including a lipid profile. cIMT was measured 
semi-automatically by ultrasound.
Results: In total 243 RA patients and 117 controls were included. The median RA disease 
duration was 7 years (IQR 2-14 years). The median DAS28 was 2.4 (IQR 1.6-3.2) and 114 
(50.4%) of the RA patients were in remission. The presence of RA and cIMT were not 
associated (univariate analysis). Multivariable regression analysis showed that cIMT in 
RA patients was associated with age (B=0.006, p<0.001) and systolic blood pressure 
(B=0.003, p=0.003). In controls, cIMT was associated with age (B=0.006, p0.001) and 
smoking (B=0.097, p=0.001). 
Conclusion: cIMT values were similar between RA patients and controls. Hypertension 
was strongly associated with cIMT in RA patients. After adjustment, no association 
between cIMT and specific RA disease characteristics were found in this well treated RA 
cohort. 
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Introduction
Rheumatoid Arthritis (RA) is a chronic systemic inflammatory disease of unknown etiol-
ogy, affecting ~1% of the adult general population (1, 2). Patients with RA have a higher 
all cause mortality risk than the general population and the leading cause of death is 
cardiovascular disease (CVD) (3-5). The evidence of the excess cardiovascular risk in 
rheumatoid arthritis (RA) has been well described (3, 5-9) and the presence of RA can be 
considered an independent risk factor for CVD (7, 10). The prevalence of CVD in patients 
with RA is as high as in patients with type 2 diabetes mellitus (7, 11). Since inflammation 
is a key event in the development of atherosclerosis (12-14) it has been proposed that 
the increased inflammatory state of patients with RA explains, at least in part, the in-
creased cardiovascular risk (8, 10, 15-17). Several RA specific risk factors such as disease 
activity, inflammatory markers and anti-CCP have been associated with an increased 
carotid intima media thickness (cIMT) and CVD risk. A recent study by Barbarroja et al. 
showed that anti-CCP antibodies act as direct inductors of the pro-oxidative status and 
the inflammatory and atherogenic profile of lymphocytes, monocytes and neutrophils in 
RA (18). In line with this report, Vázquez et al. showed an association between anti-CCP 
levels and CRP levels with an increased cIMT and CVD risk (19). Moreover, traditional risk 
factors such as hypertension, hyperlipidemia, smoking and overweight are also highly 
prevalent among RA patients (20, 21), and several studies have shown a significant un-
derdiagnosis and undertreatment of these traditional risk factors in RA (22, 23). 
The cIMT measured by ultrasound is a surrogate marker of atherosclerosis and the 
most widely used non-invasive imaging method to assess atherosclerosis and CVD risk. 
A higher cIMT reflects a (pre-) atherogenic condition and is predictive for future cardio-
vascular events (24, 25). Several studies have shown an increased cIMT in RA patients, 
even early in the course of the disease (26-30). Traditional risk factors may also play a role 
besides the inflammatory state in RA. Unfortunately, the association between traditional 
risk factors and cIMT in RA patients is still unclear (31). Increasing evidence suggests that 
a cumulative number of traditional CVD risk factors contributes to the higher CVD risk in 
RA (32). The aim of this study was to investigate which factors are associated to cIMT in 
RA patients in comparison to controls. 
Materials and Methods
Study design and subjects
A cross-sectional study was carried out in patients with RA and controls to determine 
the differences in the relationship between cIMT and clinical factors. The study was 
carried out between July 2009 and February 2013 at the Diabetes and Vascular Centre 
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and the outpatient clinic of Rheumatology of the Sint Franciscus Gasthuis, Rotterdam, 
the Netherlands. All patients with RA in this report were participants in the FRANCIS 
study, an open label randomized clinical trial to investigate the effectiveness of strict 
treatment of cardiovascular risk factors in RA (The Dutch Trialregister, NTR3873; ABR no. 
NL32669.101.10). RA patients attending the outpatient clinic from the Department of 
Rheumatology were asked to participate in the FRANCIS study. Inclusion criteria were 
the presence of RA and an age ≤70 years. Exclusion criteria were the presence of dia-
betes mellitus (DM) or CVD. CVD was defined as a documented history of myocardial 
infarction, cerebrovascular event, amputation due to peripheral artery disease, intermit-
tent claudication, or a prior percutaneus transluminal coronary angioplasty (PTCA) or 
coronary artery bypass graft (CABG). In addition, kidney disease defined as an MDRD 
<30 ml/min was an exclusion criterium. Only patients with a CVD risk <10% according 
to the 2009 version of the SCORE model were randomized. Patients aged over 65 years 
were classified as 65 years old in order to be able to use the SCORE model. Patients with 
a CVD risk ≥10% were followed in a separate cohort (“high risk cohort”). For the cur-
rent analysis, baseline data from both randomized patients and patients in the high risk 
cohort were used. The RA patients were treated by their own rheumatologists according 
to a treat-to-target principle, aiming for disease remission (DAS28<2.6). RA was defined 
by the ACR ’87 criteria (33). Unmatched control subjects were non-RA patients followed 
in a separate observational study (ABR no. NL29910.101.09) from our department. They 
were recruited from the outpatient clinic of the Diabetes and Vascular Center of the Sint 
Franciscus Gasthuis in Rotterdam and underwent measurements identical to the RA 
patients of the FRANCIS study (34). Exclusion criteria for the control group were also 
the presence of DM, CVD and/or kidney disease. All controls fulfilling the age limit of 
≤70 years were included in this analysis. In addition, RA patients and controls who used 
statins and/or anti-hypertensives were excluded. Controls with a CRP >10 mg/L were 
excluded from the analysis. Anthropometric characteristics i.e. height, weight, waist 
circumference and blood pressure were obtained as well as a detailed medical history 
and the use of medication. All subjects provided written informed consent. The studies 
were approved by the independent Regional Medical Ethical Committee Rotterdam of 
the Maasstad Hospital, the Netherlands.
Rheumatoid arthritis disease activity
Rheumatoid arthritis disease activity was assessed by using the Disease Activity Score 
with 28 joints counted (DAS28). This score included swollen joint count (28), tender joint 
count (28), VAS (0-100 scale) indicating pain/discomfort due to RA, and the erythrocyte 
sedimentation rate (ESR). We also calculated disease activity with C-reactive protein 
(CRP) instead of ESR (DAS28CRP), 
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Laboratory measurements
A standardized set of measurements was performed in each subject. Laboratory 
parameters were determined at the Department of Clinical Chemistry, Sint Franciscus 
Gasthuis, according to standard procedures. Renal and liver function tests as well as 
glucose, CRP, total cholesterol, HDL-C and triglycerides (TG) were measured using Syn-
chron LX-20 and DxC analyzers (Beckman Coulter, Anaheim CA, USA) (34, 35). LDL-C was 
calculated using the Friedewald formula if TG were below 4.60 mmol/l. Apolipoprotein 
(apo) AI and apo B were determined in serum by rate nephelometry using IMMAGE with 
commercially available kits (Beckman Coulter, Anaheim CA, USA) (31,32). In the case of 
RA patients, blood samples were obtained following the strict protocol of the FRANCIS 
study. Samples from control subjects were drawn with less strict criteria. 
Intima media thickness of the carotid arteries
Carotid ultrasound scans were carried out using the ART-LAB (Esaote, Italy) by trained 
and experienced sonographers as described earlier (34, 35). Ultrasound scans were per-
formed with the patients lying in a supine position with the head resting comfortably 
and the neck slightly hyperextended and rotated in the opposite direction of the probe. 
The ultrasound images were obtained of the distal 1 cm of the far wall of each common 
carotid artery (CCA) using B-mode ultrasound producing two echogenic lines. These 
lines represent the combined thickness of the intima and media layers of the arterial 
wall. Each CCA was imaged in three different projections: CCA right side 90-120-150 and 
CCA left side 210-240-270 degrees. The segments were measured semi-automated in 
triplicate. In some patients cIMT measurements were only partly available due to techni-
cal difficulties. In these cases, the mean cIMT was only calculated if at least measure-
ments at two different angles per side were available. 
Statistics
Data are given as mean ± standard deviation (SD) unless stated otherwise. Differences 
between groups were determined using the unpaired Student’s t-test or Chi-square 
test, where appropriate. In case of skewed variables (DAS28(-CRP) and TG), the Mann-
Whitney U test was used for comparisons between groups. For statistical analysis, 
cIMT was defined as the mean of the six individual measurements. Multivariable linear 
regression analysis was used to identify factors associated with cIMT in RA patients and 
controls. Covariables entered into the regression analysis were: age, sex, systolic blood 
pressure, waist circumference, smoking habit, glucose, apo AI, apo B, total cholesterol, 
HDL-C, LDL-C, TG, glucose, creatinin and CRP. For RA patients, the presence of rheuma-
toid factor and anti-CCP, erosive disease, disease duration, DAS28CRP, DAS28 and the 
use of methotrexate and biologicals were added to the model. Covariables showing a 
P<0.10 in the univariate analysis were entered in the multivariable analysis. In order to 
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create comparable models for RA patients and controls, a separate analysis with and 
without RA disease duration was performed for RA patients. In the case that two or more 
related parameters were highly correlated (multicollinearity), only one was selected for 
the multivariable analysis. As a result, waist circumference was selected instead of BMI; 
systolic blood pressure was selected instead of diastolic blood pressure; and LDL-C was 
chosen above apo B or TG. Significant co-variables were investigated for interaction. The 
multivariable analysis included age, sex, smoking, waist circumference, systolic blood 
pressure and LDL-C. The association between glucose and cIMT was analyzed separately 
because it was unknown which of the control subjects had their blood samples taken 
after an overnight fast. All statistical analyses were performed using PASW statistics ver-
sion 18.0 (IBM SPSS Statistics, New York, United States). P-values below 0.05 (two sided) 
were considered statistically significant.
Results
General Characteristics
243 RA patients and 117 controls were included. General characteristics of RA patients 
and controls are shown in Table 1. Both groups were comparable regarding age, gender, 
lipid profile, waist circumference, and cIMT. There were more current smokers among RA 
patients compared to controls. RA patients had a significantly higher body mass index 
(BMI) and systolic blood pressure (Table 1). 
The median RA disease duration for RA patients was 7 years (IQR 2-14 years). In total, 
107 patients (44.0%) used NSAIDS, 186 (76.5%) RA patients used methotrexate and 96 
(39.5%) used an anti-TNFα or other biological agent. Of the 96 patients with a biological 
agent, 25 (26%) used no methotrexate and 71 (74%) used a combination of methotrex-
ate and a biological. 
The median DAS28 was 2.4 (IQR 1.6-3.2). In total, 114 (50.4%) of the RA patients had 
a DAS28 <2.6 implying disease remission, 48 (21.2%) had low disease activity (DAS28 
2.6-3.1), 47 (20.7%) had moderate disease activity (DAS28 3.1-5.1) and 17 (7.5%) had 
high disease activity (DAS28 ≥ 5.1). When applying DAS28CRP, the results were similar: 
the median DAS28CRP was 2.2 (IQR 1.6-2.9), 113 (58.8%) had disease remission, 39 
(17.3%) had low disease activity, 40 (17.7%) had moderate disease activity and 14 (6.2%) 
had high disease activity. cIMT did not differ between RA groups based on their disease 
activity (data not shown). 
Univariate analysis
To identify the covariables associated with cIMT, univariate regression analysis was car-
ried out in RA patients, controls and the combined patient and control group (Table 2). 
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In all groups age, systolic blood pressure, LDL-C and apo B showed a significant associa-
tion with cIMT. Furthermore, in controls, current smoking was significantly associated 
with cIMT. In RA patients male gender, BMI, waist circumference, TG, glucose and disease 
duration were significantly associated with cIMT. The correlation coefficient between RA 
disease duration and age was 0.262. A trend towards a positive association between 
anti-CCP positivity and cIMT was observed (B=0.033(-0.044-0.070); p=0.078) (Table 2). 
When these univariate analyses were performed only in RA patients not using biologi-
cals, the associations between cIMT and anti-CCP positivity, disease duration, glucose 
and TG were no longer statistically significant (data not shown). Other parameters 
showed similar associations as in the total RA group. 
Multivariable analysis
Multivariable regression analysis with identified covariables associated with cIMT, was 
performed in RA patients, controls and in both groups combined (Table 3). In controls 
Table 1. General Characteristics. Data presented as mean ± standard deviation or n (%) unless stated oth-
erwise.
 RA-patients 
(n = 243)
Controls
(n = 117)
P-value
Male 79 (32.5%) 46 (39.3%) 0.204
Age (yrs) 51.8±11.6 50.0±12.1 0.186
Current smoker (n,%) 54 (22.2%) 16 (13.7%) 0.051
Weight (kg) 76.3±14.4 75.3±14.5 0.520
BMI (kg/m2) 26.1±4.3 24.9±3.7 0.006
Systolic blood pressure (mmHg) 129±18 124±13 0.004
Waist circumference (cm) 93±14 90±12 0.054
Total cholesterol (mmol/l) 5.4±1.1 5.6±1.2 0.147
LDL-C (mmol/l) 3.4±1.0 3.5±1.0 0.372
HDL-C (mmol/l) 1.54±0.51 1.55±0.43 0.894
TG (mmol/l)* 1.03 (0.72-1.42) 1.12 (0.74-1.61) 0.182
Apo AI (g/l) 1.71±0.36 1.65±0.32 0.099
Apo B (g/l) 1.00±0.26 1.04±0.30 0.192
Glucose (mmol/l) 5.4±0.5 5.2±0.9 0.002
C-reactive protein (mg/l)* 2.00 (1.00-5.00) 1.00 (1.00-2.75) <0.001
cIMT (mm) 0.556±0.120 0.573±0.134 0.220
Rheumatoid Factor positivity (n,%) 150 (61.7%)** NA
Anti-CCP positivity (n,%) 142 (58.4%)*** NA
BMI = body mass index TG = triglycerides; Apo = apolipoprotein; cIMT = carotid intima media thickness; 
NA = not available
* Data presented as median (interquartile range), difference between groups tested with the Mann-Whit-
ney U test. ** data available in 235 patients. *** data available in 204 patients.
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cIMT was significantly associated with age and current smoking and in RA patients with 
age and systolic blood pressure. These results remained unchanged after including 
glucose in the analysis. In RA patients, additional multivariable analyses including RA 
disease duration alone and combined with anti-CCP were performed (Table 4). The ad-
dition of RA disease activity and anti-CCP positivity, alone or combined, did not improve 
the predictive power of the original multivariable model (Table 4). Multivariable analysis 
in only those RA patients not using biological therapy showed comparable results.
Table 2. Univariate regression analysis identifying covariables associated with cIMT.
Variable Controls (n=117) RA patients (n=243) Total population (n=360)
B (95% CI) p-value B (95% CI) p-value B (95% CI) p-value
Age (yrs) 0.006 (0.004-0.007) <0.001 0.006 (0.005-0.007) <0.001 0.006 (0.005-0.007) <0.001
Male sex 0.021 (-0.029-0.071)  0,243 0.050 (0.018-0.082) 0.002 0.041 (0.014-0.068) 0.003
Smoking 0.097 (0.028-0.166) 0.006 0.016 (-0.021-0.053) 0.403 0.034 (0.001-0.067) 0.044
BMI (kg/m2) 0.005 (-0.002-0.012) 0.139 0.005 (0.001-0.008) 0.010 0.004 (0.001-0.007) 0.006
Waist (cm) 0.002 (0.000-0.004) 0.101 0.002 (0.001-0.003) <0.001 0.002 (0.001-0.003) <0.001
BPs (mmHg) 0.002 (0.001-0.004) 0.009 0.003 (0.002-0.004) <0.001 0.003 (0.002-0.003) <0.001
BPd (mmHg) 0.000 (-0.003-0.003) 0.963 0.004 (0.002-0.005) <0.001 0.003 (0.001-0.004) <0.001
LDL-C (mmol/l) 0.043 (0.019-0.066) <0.001 0.034 (0.020-0.049) <0.001 0.037 (0.025-0.050) <0.001
HDL-C (mmol/l) -0.010 (-0.066-0.047) 0.740 -0.010 (-0.040-0.020) 0.511 -0.010 (-0.037-0.017) 0.476
Apo AI (g/l) 0.013 (-0.065-0.091) 0.750 -0.016 (-0.059-0.027) 0.473 -0.010 (-0.048-0.028) 0.610
Apo B (g/l) 0.114 (0.034-0.194) 0.005 0,131 (0.075-0.187) <0.001 0.126 (0.081-0.172) <0.001
TG (mmol/l)* 0.013 (-0.020-0.045) 0.441 0.026 (0.003-0.049) 0.026 0.022 (0.003-0.040) 0.022
Glucose (mmol/l)* 0.009 (-0.019-0.036) 0.536 0.044 (0.016-0.072) 0.002 0.021 (0.001-0.040) 0.029
CRP (mg/dl) -0.000 (-0.014-0.014) 0.964 0.001 (-0.001-0.003) 0.504 0.000 (-0.002-0.002) 0.731
Creatinin (umol/l) 0.001 (-0.001-0.003) 0.549 0.002 (0.001-0.003) 0.002 0.001 (0.001-0.003) 0.002
Absence of RA - - - - 0.017 (-0.010-0.045) 0.220
Anti-CCP - - 0.033 (-0.004 -0.070) 0.078
Rheumatoid 
factor
- - 0.020 (-0.013-0.053) 0.231
Erosive Disease - - 0.020 (-0.011-0.051) 0.212
DAS28 - - 0.005 (-0.009-0.019) 0.494
DAS28CRP - - -0.001 (-0.017-0.015) 0.902
Disease duration - - 0.002 (0.001-0.004) 0.012
Methotrexate - - 0.001 (-0.036-0.037) 0.976
Biological agents - - -0.07 (-0.039-0.024) 0.651
RA = Rheumatoid arthritis, BPs = systolic blood pressure, BPd = diastolic blood pressure, TG = triglycerides, 
DAS28 = RA disease activity score 28 joints
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Discussion
Surprisingly, cIMT in RA patients was similar to the cIMT of control subjects without RA, 
which is in contrast to other studies, showing increased cIMT in RA patients even early in 
the course of the disease (29, 30, 32, 36-38). It is even more surprising since in our study 
RA patients had a higher BMI, systolic blood pressure, glucose and CRP and, a larger 
percentage of RA patients smoked compared to controls.
A post hoc sample size calculation showed that our sample sizes of 243 RA-patients 
and 117 control patients are not sufficiently large to support the presence of a signifi-
cant difference in mean cIMT between the groups with 80% power. However, consider-
ing that the difference in mean cIMT we found (0.017) cannot be considered clinically 
Table 3. Multivariable regression analysis with identified covariables associated with cIMT.
Variable
Controls (n=117)
R2=0.321
RA patients (n=243)
R2=0.391
Total population (n=360)
R2=0.347
B (95% CI) p-value B (95% CI) p-value B (95% CI) p-value
Age (yrs) 0.005 (0.003-0.007) <0.001 0.005 (0.004-0.006) <0.001 0.005 (0.004-0.006) <0.001
Male sex 0.010 (-0.037-0.056) 0.678 0.013 (-0.014-0.040) 0.336 0.015 (-0.008-0.038) 0.201
Smoking 0.101 (0.041-0.162) 0.001 0.019 (-0.011-0.049) 0.207 0.034 (0.007-0.061) 0.014
Waist (cm) 0.002 (0.000-0.004) 0.127 0.001 (0.000-0.002) 0.142 0.001 (0.000-0.002) 0.106
BPs (mmHg) 0.001 (-0.001-0.002) 0.488 0.001 (0.000-0.002) 0.003 0.001 (0.000-0.002) 0.012
LDL-C (mmol/l) 0.009 (-0.016-0.034) 0.467 0.007 (-0.006-0.020) 0.270 0.009 (-0.003-0.020) 0.143
Apo B (g/l) ** ** **
RA = Rheumatoid arthritis, BPs = systolic blood pressure, Apo = apolipoprotein
** When using apoB instead of LDL similar results were found. 
Table 4. Multivariable regression analysis including RA disease characteristics.
Variable
RA patients (n=243)
R2=0.39
RA patients (n=243)
R2=0.40
B (95% CI) p-value B (95% CI) p-value
Age (yrs) 0.005 (0.004-0.006) <0.001 0.005 (0.004-0.007) <0.001
Male sex 0.005 (-0.016-0.039) 0.409 0.005 (-0.026-0.035) 0.786
Smoking 0.019 (-0.011-0.049) 0.212 0.020 (-0.02-0.053) 0.220
Waist (cm) 0.001 (0.000-0.002) 0.156 0.001 (0.000-0.002) 0.216
BPs (mmHg) 0.001 (0.000-0.002) 0.002 0.001 (0.000-0.000) 0.005
LDL-C (mmol/l) 0.007 (0.006-0.020) 0.282 0.007 (-0.008-0.021) 0.365
RA disease duration (yrs) 0.000 (-0.002-0.001) 0.579 0.000 (-0.002-0.002) 0.792
Anti-CCP - - 0.007 (-0.024-0.037) 0.661
RA = Rheumatoid Arthritis, BPs = systolic blood pressure
82 Chapter 5
meaningful, one would need to include (at least) 270 RA and control patients (at an 
equivalence margin of 0.05; or 68 patients at an equivalence margin of 0.10) to support 
that a difference in cIMT is absent. In summary, our sample sizes are sufficiently large to 
support that a clinically meaningful difference in cIMT in our study is absent, with 90% 
power.
One of the reasons for this difference with other studies may be the relatively low 
disease activity in our RA patients. A higher RA disease activity results in an increased 
cardiovascular risk. The RA disease activity in our study was low with a total of 70% of RA 
patients in clinical remission or with low disease activity, which may have had a benefi-
cial effect on cIMT. When we compared cIMT in RA patients with disease remission or low 
disease activity with cIMT in RA patient with moderate or high disease activity, no dif-
ferences in cIMT were found. This may be due in part to the small proportion of patients 
with moderate to high disease activity. Our outpatient clinic of Rheumatology is a large 
outpatient clinic that consists of a large and representative sample of RA patients in the 
Netherlands. At the outpatient clinic, a structured tight control regimen of RA disease 
activity is carried out reflecting the present situation in the Netherlands. Therefore, we 
believe that the sample of RA patients in this study is representative for the general 
Dutch RA population, although the results may not apply to RA patients with higher 
average disease activity. A meta- analysis by Ambrosino et al. reported outcomes of 59 
studies on cIMT in RA compared to controls (30). Not all studies included information on 
disease activity, but the mean DAS28 of those studies reporting disease activity ranged 
from 2.6 to 6.2, which is higher than our reported median DAS28 of 2.4. Of those 59 
studies, 51 reported an increased cIMT in RA patients compared to controls (30). Only 2 
studies reported DAS28 levels <3.0 showing conflicting results concerning differences 
in cIMT in RA compared to controls (39, 40). The same meta-analysis by Ambrosino et 
al. showed that a higher inflammatory status (DAS28, CRP, ESR) was associated with an 
increased cIMT (30). 
Besides disease activity, several RA specific risk factors, such as the presence of rheu-
matoid factor, anti-CCP and erosive disease, are considered risk factors for atheroscle-
rosis. They are all surrogate markers for the inflammatory burden since the presence of 
rheumatoid factor and/or anti-CCP often results in a higher disease activity. Also erosive 
disease occurs mostly in patients with long periods of uncontrolled disease activity. In 
our cohort with generally a low disease activity, rheumatoid factor and anti-CCP positiv-
ity were not associated with cIMT in the multivariable model. These results are in line 
with several other studies that could not demonstrate an association between these 
parameters and cIMT (37, 39). A limitation of our study was that only qualitative data on 
rheumatoid factor and anti-CCP were available, since these characteristics were not re-
tested at the time of inclusion. Recently, an in vitro study showed a positive correlation 
between the level of anti-CCPs and overexpression of thrombotic, inflammatory and 
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pro-oxidative markers in leukocytes (18). We did find a crude (univariate) association 
between disease duration and cIMT, but this association was no longer significant in 
the multivariable model. This is in line with a recent publication by Arts et al. who found 
that the risk of CVD in RA patients was not increased after 10 years of disease duration 
when compared to the first 10 years (40). Data on the association between cIMT and RA 
disease duration are conflicting since several other studies reported a positive associa-
tion between cIMT and RA disease duration (37, 41, 42). 
Traditional cardiovascular risk factors such as smoking, overweight, hyperlipidemia 
and hypertension are highly prevalent in RA patients and can be easily treated by life-
style and pharmacological interventions. Nevertheless, underdiagnosis and undertreat-
ment of these risk factors in RA patients have been described (22, 23, 43). An association 
between cIMT and blood pressure both in the general population and in RA patients 
has been described previously (17, 27, 44-46). In the present paper, regression analyses 
underline the association of systolic blood pressure on cIMT in RA patients. These data 
underscore the importance of adequate blood pressure regulation in RA. 
No association between cIMT and lipid levels was found. Hyperlipidemia was strongly 
associated to cIMT in the univariate analysis, but it was no longer significant in the mul-
tivariable analysis after adjustment for other covariables. In contrast to the association 
found between smoking and cIMT in controls, no association between smoking and 
cIMT in RA patients was found. This is in line with earlier results reported by Gonzalez et 
al., who found a weaker association between smoking and CVD risk in RA patients than 
in non-RA patients (47). 
In conclusion, in this RA cohort with relatively low disease activity, cIMT was not 
increased compared to controls and cIMT was not associated with RA disease character-
istics. Hypertension was strongly associated with cIMT in RA patients. In light of these 
results and based on findings from other studies, treatment of hypertension and other 
traditional CVD risk factors in RA seems warranted to reduce cardiovascular risk in RA. 
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Abstract 
Background and aims: Serum concentrations of apolipoprotein (apo) B48, the structural 
protein of chylomicrons, are increased in conditions associated with systemic inflamma-
tion. As such, apo B48 may help to identify patients at increased cardiovascular risk. The 
objective of this study was to evaluate apo B48 levels in relation to other cardiovascular 
risk factors in patients with rheumatoid arthritis (RA). 
Methods: We performed a prospective cohort study with RA patients without clinical 
cardiovascular disease or diabetes mellitus. Blood samples were collected after an over-
night fast and a complete lipid profile, including total serum apo B and apo B48 (ELISA), 
was measured. 
Results: 328 Patients were included. The mean age was 53±11 years and 224 patients 
(68%) were female. Remnant cholesterol (remnant-C) concentration was 0.52±0.26 
mmol/L and fasting plasma triglycerides 1.25±0.88 mmol/L Median plasma apo B48 
was 8.6 [IQR 5.2-12.5]. Serum apo B48 correlated positively with triglycerides (r=0.651; 
p<0.001, remnant-C (r=0.479; p<0.001 and LDL-C (r=0.123; p=0.03). Patients in the high-
est apo B48 tertile were, compared to the lowest tertile, more often rheumatoid factor 
positive 75% [n=72] vs. 58% [n=62]; p=0.04) and anti-CCP positive (75% [n=62] vs. 59% 
[n=59]; p=0.005). 
Conclusion: RA patients have a high level of apo B48, despite low plasma triglycerides 
and remnant-C, which indicates that chylomicron remnant clearance may be delayed in 
RA, especially in rheumatoid factor or anti-CCP positive subjects.
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Introduction
The evidence on the increased cardiovascular disease (CVD) risk associated to rheuma-
toid arthritis (RA) has accumulated during the last two decades. The prevalence of CVD 
in patients with RA is as high as in patients with type 2 diabetes mellitus (T2DM) (1, 2). 
Traditional cardiovascular risk factors, such as hyperlipidemia and hypertension, as well 
as RA specific risk factors, such as RA disease activity, erythrocyte sedimentation rate 
and C-reactive protein (CRP) levels contribute to the total CVD risk of RA patients (3-6). 
Postprandial hyperlipidemia with accumulation of remnants has gained interest in the 
literature because of recent reports showing that non-fasting triglycerides are indepen-
dent predictors of the risk of atherosclerosis (7, 8). Postprandial hyperlipidemia is often 
present in patients with a high CVD risk, such as patients with established coronary 
artery disease (CAD), T2DM (9, 10), the metabolic syndrome (11, 12), obesity (13) and 
familial combined hyperlipidemia (FCH) (14). Moreover, postprandial hyperlipidemia is 
closely associated to the generation of atherosclerosis (15-17). Postprandial chylomi-
crons and their remnants are able to induce leukocyte activation and can be internalized 
by macrophages without the need for prior modification, causing foam cell formation 
(18) and therefore, initiate atherosclerosis (19).
Postprandial hyperlipidemia is usually the consequence of hepatic very low-density 
lipoprotein (VLDL) overproduction and delayed clearance of chylomicrons and VLDL 
with their respective remnants since they share the same metabolic pathway (11, 14, 
20, 21). In T2DM, intestinal overproduction of chylomicrons has been demonstrated, 
which also contributes to the postprandial hyperlipidemia typical of this disorder (22). 
Overall, these metabolic processes lead to elevated concentrations of chylomicrons and 
VLDL, and their respective remnants, collectively known as triglyceride-rich lipoproteins 
(TRLs). All these atherogenic lipoproteins contain apolipoprotein (apo) B as structural 
protein. In humans, two forms of apo B exist: apo B100, which is found on hepatically 
derived lipoproteins, and apo B48, which is present on the intestinally derived chylo-
microns and their remnants (23). Therefore, plasma apo B48 levels represent the exact 
number of circulating chylomicrons and chylomicron remnants. 
Apo B48 levels are closely associated to postprandial lipoprotein metabolism, even in 
the fasting state, and elevated levels of fasting apo B48 reflect postprandial hyperlipid-
emia (24). Moreover, fasting apo B48 is positively associated with several cardiovascular 
risk factors, including plasma triglycerides, remnant-cholesterol (remnant-C), body mass 
index (BMI) and carotid intima-media thickness (cIMT), a surrogate marker for subclinical 
atherosclerosis, and it correlates negatively with high-density lipoprotein cholesterol 
(HDL-C) (25, 26). 
To date, no data on apo B48 or postprandial lipemia in RA are available. The chronic 
inflammatory state in RA may be associated to impaired chylomicron (remnant) me-
92 Chapter 6
tabolism, which in turn may contribute to the increased risk of CVD in these patients. 
Therefore, we aimed to evaluate apo B48 levels in RA in relation to other cardiovascular 
risk factors. 
Materials and methods
Participants
RA patients in this study were participants in the FRANCIS (Franciscus Rheumatoid Ar-
thritis and Cardiovascular Intervention Study) trial. The FRANCIS study is an open label 
randomized clinical trial in which RA patients younger than 70 years old and without 
current CVD or T2DM are routinely screened for traditional CVD risk factors and, based 
on randomization, strictly treated for traditional CVD risk factors, at the Diabetes and 
Vascular Center of the Franciscus Gasthuis, Rotterdam, the Netherlands (27, 28). CVD 
was defined as a prior myocardial infarction, cerebrovascular event, amputation due to 
peripheral artery disease, intermittent claudication, percutaneous transluminal coro-
nary angioplasty (PTCA) or coronary artery bypass graft (CABG). T2DM was defined as 
fasting glucose > 7.0 mmol/l. The data for this study are the baseline measurements in 
the FRANCIS study (registered at trialregister.nl, number NTR3873).
Approval was given by the Institutional review board of the Franciscus Gasthuis and 
the regional independent medical ethical committee at the Maasstad Hospital in Rot-
terdam. All participants gave written informed consent.
Data collection
The medical history, anthropometric measures and the use of medication were recorded. 
RA disease activity was assessed by using the Disease Activity Score with 28 joints 
counted (DAS28). This score included swollen joint count (28), tender joint count (28), 
VAS (0-100 scale) indicating pain/discomfort due to RA, and the erythrocyte sedimenta-
tion rate (ESR). 
The estimated cardiovascular risk was assessed using the SCORE tables, and included 
suggested adaptations according to EULAR 2015 recommendations. The EULAR recom-
mendation implies a multiplication of the CVD risk by 1.5 for all RA patients (29). 
Blood samples were taken after an overnight fast of at least 12 hours and included a 
complete lipid profile with both total plasma apo B and apo B48. 
Analytical Methods
Basic parameters for renal and liver function as well as glucose, total cholesterol, HDL-C 
and triglycerides were determined using a Synchron LX-20 or DxC analyzers (Beckman 
Coulter, Brea CA, USA) according to standard procedures in our laboratory for clinical 
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chemistry. LDL-C values were calculated using the Friedewald formula. Remnant-C was 
calculated by subtracting LDL-C and HDL-C from the total cholesterol. Apo AI and apo 
B were determined by rate nephelometry using an IMMAGE analyzer (Beckman Coulter, 
Brea CA, USA). The ESR was measured using an Alifax Test 1 analyzer (Alifax, Padova, 
Italy). 
Apo B48 serum levels were quantified as previously reported (30), using a commer-
cially available ELISA (Shibayagi Co., Ltd. Japan), consisting of a Sandwich type ELISA 
with absorbance dichromatic reading at 450 nm/ 620 nm (reference for plate correction) 
wavelength (31). All samples were assayed in three runs. Since no commercial quality 
controls are available for apo B48, a local internal quality control was pooled according 
to WHO recommendations, stored at - 80 ºC, and formerly assayed by duplicate on each 
plate in parallel to samples. Calculated Variation Coefficients (VC) were 5.7% (intra-
assay), 11.0% (inter-assay) and 12.4% (total).
Statistics
Data are given as mean ± standard deviation (SD) unless stated otherwise. Correlation 
analysis was performed using a Pearson’s correlation. For comparison of patients with 
relatively high and low apo B48 levels, tertiles were created. Analyses were performed 
between the lowest and the highest tertile. Analyses were performed using the Stu-
dents t-test or chi-square test where applicable. For skewed variables (DAS28, C-reactive 
protein, triglycerides) the Mann-Whitney U test was used. All statistical analyses were 
carried out using PASW statistics version 18.0 (IBM SPSS Statistics, New York, United 
States). P-values below 0.05 (two sided) were considered statistically significant. 
Results 
General characteristics
In total, 328 subjects with RA were included. The general characteristics are shown in 
Table 1. Most patients were female (n=224; 68%) and their age was 53 ± 11 years. The 
median RA disease duration was 7 [IQR 2-14] years. The median DAS28 was low, indicat-
ing low RA disease activity or remission. Most RA patients (73%; n=243) used methotrex-
ate and 39% (n=127) received biological therapy. Daily prednisone in varying dosage 
was used in 12% (n=40). A CVD risk of <10% was found in 57% (n=188), 23% (n=77) had 
a CVD risk of 10-19% and 18% (n=60) had a CVD risk ≥20%. In six patients CVD risk could 
not be calculated due to missing data.
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Correlation studies
Remnant cholesterol (remnant-C) concentration was 0.52±0.26 mmol/L and fasting 
plasma triglycerides 1.25±0.88 mmol/L. The median apo B48 was 8.6 [IQR 5.2-12.5] mg/L. 
Apo B48 correlated positively with triglycerides (r=0.651; P<0.001), remnant-C (r=0.479; 
P<0.001), total cholesterol (r=0.196; P< 0.001), LDL-C (r=0.123; p=0.03) and total serum 
apo B (r=0.261; p<0.001) (Figure 1). A negative correlation was found between apo B48 
and HDL-C (r=-0.208; P<0.001). A positive trend was observed between apo B48 and 
glucose (r=0.106; p=0.06), and between apo B48 and systolic blood pressure (r=0.095; 
p=0.09). No significant correlation was found between apo B48 and BMI (r=0.014; 
p=0.81), waist circumference (r=0.067; p=0.23) or DAS28 (r=-0.03; p=0.58).
General characteristics based on apoB48 tertiles
Tertiles based on apo B48 levels showed that patients in the highest tertile were more 
often male (43% [n=46] vs. 28% [n=31]; p=0.03), were older (55±9 vs. 53±12 years; 
p=0.018) and more often anti-CCP positive (75% [n=62] vs. 59% [n=59]; p=0.005) and 
rheumatoid factor positive (75% [n=72] vs. 58% [n=62]; p=0.04) compared to the lowest 
Table 1. General characteristics of study participants (n=328). Data are given as mean ± SD, number (%) or 
as median [Interquartile Range].
RA
(n=328) 
Male (n,%) 104 (32%)
Age (yrs) 53 ± 11
BMI (kg/m2) 26.5 ± 4.5
Current Smoker 60 (18%)
Systolic BP (mmHg) 132 ± 19
Diastolic BP (mmHg) 79 ± 10
Glucose (mmol/L) 5.5 ± 0.6
Total cholesterol (mmol/L) 5.4 ± 1.1
LDL-C (mmol/L) 3.4 ± 0.9
HDL-C (mmol/L) 1.48 ± 0.41
Triglycerides (mmol/L) 1.05 [0.73-1.51]
Apo AI (g/L) 1.69 ± 0.40
Apo B (g/L) 1.00 ± 0.26
Apo B48 (mg/L) (median [IQR]) 8.6 [5.2-12.5]
Remnant-C (mmol/L) 0.52 ± 0.26
Medication use
Lipid lowering drug (n,%) 15 (5%)
Antihypertensive drugs (n,%) 56 (17%)
RA disease activity (DAS28) (median [IQR]) 2.30 [1.60-3.24]
CAD = coronary artery disease; BP = blood pressure; Remnant-C = total cholesterol -(LDL-C) – (HDL-C). 
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tertile. Triglycerides were higher in the highest tertile compared to the lowest tertile 
(median 1.49 [IQR 0.93-2.01] mmol/L vs. median 0.83 [IQR 0.65-1.09] mmol/L; p <0.001). 
The median [IQR] apo B48 was 4.4 [3.7-5.2] mg/L in the lowest tertile and 14.6 [12.4-18.5] 
mg/L in the highest tertile.
No differences were found in total cholesterol, LDL-C, HDL-C, DAS28, C-reactive 
protein, RA disease duration, the presence of erosive disease, DMARD use, statin use or 
prednisone use (data not shown). 
Discussion
This is the first study to explore apo B48 levels in RA patients, showing elevated plasma 
concentrations, with a median apo B48 of 8.6 [5.2-12.5] mg/L, compared to previous 
studies in healthy controls. Alipour et al. found apo B48 levels of 5.7±0.6 mg/L in healthy 
individuals and Masuda et al. found apo B48 levels of 3.9 ± 2.4 mg/L in non-CAD patients 
without overt coronary stenosis (26, 32). In another study, Masuda et al. investigated 
apo B48 levels in different subgroups of healthy controls. They concluded that apo B48 
levels of 5.7 mg/L should be regarded as the upper limit of normal apo B48 levels in 
normolipidemic healthy controls (33). Interestingly, the highest apo B48 tertile in our 
RA group showed threefold increased levels compared to this suggested reference 
value. Although the triglyceride concentrations were higher in this tertile, those levels 
Figure 1. Correlations of apolipoprotein (apo) B48 with triglycerides (A), LDL-C (B), total cholesterol (C), 
remnant-cholesterol (D), apo B (E) and body mass index (F).
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were still within normal limits. Patients in the highest apo B48 tertile were significantly 
more often anti-CCP and rheumatoid factor positive. Anti-CCP and rheumatoid factor 
are associated with a more progressive disease course of the RA and thus with more 
inflammation. Patients in the highest tertile did not show a higher C-reactive protein, 
DAS28 of RA disease duration and they had not more often erosive disease. Therefore, 
the exaggerated apo B48 levels in this subgroup remain unexplained.
Apo B48, remnant-C and triglycerides are all markers of postprandial lipemia and rep-
resent different components of the lipoprotein fractions. Apo B48 reflects the number 
of circulating chylomicrons and their respective remnants, while remnant-C and plasma 
triglycerides reflect the lipid content within the chylomicrons and remnants, including 
VLDL and its remnants. Interestingly, apo B48 was increased in RA while triglycerides 
and remnant-C were within normal range, reflecting a high number of circulating, rela-
tively small and probably cholesterol-depleted remnants. Therefore, in RA the lipolysis 
of chylomicrons may be normal, while the hepatic catabolism of chylomicron remnants 
may be impaired. Alternatively, the intestinal production of chylomicrons may be in-
creased, similar to the situation in T2DM (22). Further investigation of the metabolism of 
triglyceride-rich lipoproteins and the role of postprandial hyperlipidemia on the excess 
CVD risk in RA patient is necessary. It would be interesting to know whether there is an 
association between apo B48 and levels of auto-antibodies. These data were unavailable 
in this study.
In conclusion, apo B48 levels in RA patients are high, despite low triglycerides and 
remnant-C, which indicates that chylomicron remnant clearance may be delayed in RA. 
The current data suggest an association between apo B48 levels with rheumatoid factor 
or anti-CCP positivity in RA.
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Abstract
Introduction: RA patients are characterized by an increased cardiovascular disease 
(CVD) risk in which traditional CVD risk factors and RA specific risk factors may play a 
role. In this study we investigated the effect of a tight control regimen on CVD risk fac-
tors after two years of follow-up.
Material and Methods: RA patients ≤70 years of age without CVD and diabetes mellitus 
were randomized between strict treatment of CVD risk factors or usual care. 
Results: In total 239 patients were included (109 patients in the usual care group and 
121 in the tight control group). The majority of the patients was female (n=151; 63%) 
and mean age was 54±11 years. After two years of follow-up total cholesterol, LDL-C, 
and apolipoprotein B levels were significantly lower in the tight control group compared 
to usual care. There was a trend towards lower triglycerides (p=0.05) and higher HDL-C 
(p=0.07) in the tight control group after 2 years. The LDL-C decrease was greater in the 
tight control group compared to the usual care group (-0.99±0.99 vs -0.37±0.76 mmol/l; 
p=0.03). Systolic blood pressure significantly decreased in the tight control group, but 
was blood pressure at 2-year follow up was not significantly different between the 
groups. 
Conclusion: Tight control treatment of traditional CVD risk factors in RA was most effec-
tive in targeting lipid levels after two years compared to usual care. 
Trial Registration: The Dutch Trial Register, www.trialregister.nl, NTR3873.
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Introduction
The evidence on the increased risk for cardiovascular disease (CVD) in rheumatoid 
arthritis (RA) has accumulated during the last two decades (1-3). It has been suggested 
that the prevalence of CVD in patients with RA is as high as in patients with type 2 dia-
betes mellitus (T2DM) (1, 4). The exact cause of this increased CVD risk is unclear. Since 
atherosclerosis is an inflammatory process (5) the on-going inflammation in RA may play 
a role. It is thought that tight control of RA disease activity may help to decrease the 
CVD risk in RA (6, 7). Despite the fact that their exact role is unclear, traditional CVD 
risk factors such as hypercholesterolemia and hypertension should not be overlooked 
(8-10). Several studies showed that the prevalence of hypertension and hyperlipidemia 
in RA patients is comparable to the general population. Furthermore, there is evidence 
of underdiagnosis and undertreatment of traditional CVD risk factors in RA (11, 12). The 
importance of these risk factors has been strengthened by recent national and interna-
tional recommendations proposing the need for a CVD risk estimation specifically for 
RA patients using an adapted version of the traditional SCORE risk assessment model 
(13, 14). These modifications of the original risk stratification models may have a large 
impact on current care, since the number of patients eligible for risk assessment, treat-
ment and follow-up will increase substantially. Several studies showed positive effects 
of treatment with lipid lowering drugs and/or anti-hypertensive drugs on respectively 
lipid levels and blood pressure (15-19). To date, however, the effect of a tight treatment 
regimen for these CVD risk factors on the development of clinical and subclinical ath-
erosclerosis has not been investigated. The FRANCIS study was designed to evaluate 
the effects of a predefined tight treatment protocol including all traditional CVD risk 
factors on subclinical atherosclerosis in RA comparing the effects to control patients 
who were referred to their general practitioner for treatment. In this interim analysis, we 
show the results of tight treatment of the CVD risk factors versus usual care after 2 years 
of follow-up. 
Material and Methods
Study design and patients
The FRANCIS (Franciscus Rheumatoid Arthritis and Cardiovascular Intervention Study) is 
an open label, randomized clinical trial in RA patients investigating the effects of a strict 
treatment protocol for traditional CVD risk factors like hyperlipidemia, hypertension, 
smoking, overweight and diabetes mellitus (Dutch Trial Register, www.trialregister.nl, 
NTR3873). RA patients younger than 70 years of age and without clinical CVD or T2DM 
were either randomized to intensive treatment of traditional CVD risk factors with pre-
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specified treatment targets and recommendations on lifestyle changes or they were 
referred to their general practitioner for treatment. Before randomization the CVD risk 
score according to the 2010 unadjusted SCORE risk assessment was calculated (20). Pa-
tients with a CVD risk score <10% were eligible for randomization (comparable to <20% 
in the current, unadjusted SCORE table). Patients with a CVD risk score ≥10% (9/326) all 
were treated according to the tight control protocol and were separately followed. Clini-
cal CVD was defined as a prior myocardial infarction, cerebrovascular event, amputation 
due to peripheral artery disease, intermittent claudication, percutaneous transluminal 
coronary angioplasty (PTCA) or coronary artery bypass graft (CABG). T2DM was defined 
as fasting glucose >7.0 mmol/l. All patients at inclusion were routinely screened for 
traditional CVD risk factors at the Diabetes and Vascular Centre, Franciscus Gasthuis, 
Rotterdam, the Netherlands. 
The Institutional Review Board of the Franciscus Gasthuis in Rotterdam and the TWOR 
regional independent medical ethics committee, Maasstad Hospital, Rotterdam, ap-
proved the study. The study was conducted according to the Declaration of Helsinki. All 
participants gave written informed consent. 
Treatment targets according to the tight control protocol
The flow chart for the tight control treatment regimen is shown in Figure 1. The start of 
anti-hypertensive drugs and or alteration of current anti-hypertensive treatment was 
initiated when a patients blood pressure was >140/85mmHg. The presence of hyper-
tension was confirmed by taking a mean blood pressure of 5 measurements within 15 
minutes or, if necessary an ambulant 24-hours ambulant blood pressure measurement. 
First choice of antihypertensive drug was an ACE inhibitor (perindopril), followed by the 
addition of a thiazide diuretic (indapamide) and eventually a beta and/or alpha blocker 
and/or calcium-antagonist when blood pressure persisted >140/85 mmHg.
Treatment with simvastatin in combination with dietary and lifestyle advices was initi-
ated when LDL-C was >3.0 mmol/l, apolipoprotein (apo) B >0.9 g/L or triglycerides (TG) 
>2.20 mmol/l. Bezafibrate combined with dietary and lifestyle advices were initiated in 
case of isolated hypertriglyceridemia (TG >2.20 mmol/l). Dietary and lifestyle advices 
were given in the case of low HDL-C levels (≤1.20 mmol//l for females and ≤1.00 mmol/l 
for males) and/or a body mass index (BMI) >25kg/m2. 
In the case of smoking, cessation was advised and a referral to the outpatient clinic 
for smoking cessation was offered. In the case of HbA1c levels >6.4% (48 mmol/mol) 
indicating the development of diabetes mellitus, patients were treated with metformin. 
Patients in the tight control group visited the outpatient clinic routinely every six 
months (which is similar to the appointments of the usual care group), but extra ap-
pointments were made when necessary due to medical/treatment related problems.
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Cardiovascular risk assessment
The 10-year cardiovascular risk was assessed using the SCORE tables following the 2011 
Dutch CVRM guideline (13, 14).
  
 
 
 
LDL-cholesterol 
>3.0 mmol/l simvastatin 
40mg or equivalent + 
dietary advice 
≤3.0 mmol/l no 
treatment 
≤3.0 mmol/l continue 
treatment 
>3.0 mmol/l 
simvastatin 80mg or 
equivalent 
Triglycerides 
>2.2 mmol/l  dietary advice 
+ start bezafibraat when 
isolated or start 
simvastatin 40mg 
≤2.2 mmol/l no treatment 
≤2.2 mmol/l continue 
treatment 
 
>2.2 mmol/l increase 
statin or fibrate when 
applicable 
HDL-cholesterol 
male <1 mmol/l and female >1.2 
mmol/dietary and lifestyle advise 
 
male >1 mmol/l no action 
female >1.2 mmol/l no action 
Apolipoprotein B 
>0.9 g/l start 
simvastatin 40mg or 
equivalent 
≤ 0.9g/l no treatment 
≤0.9 g/l continue therapy 
 
>0.9g/l 80mg simvastatin 
or equivalent 
Blood pressure 
>140/85 start perindopril 
4mg to a max. of 8mg 
≤140/85 no 
treatment 
≤140/85 continue 
treatment 
>140/85 add 
indapamide 
≤140/85 
continue 
treatment 
>140/85  add a 
calcium channel 
blocker, alpha blocker 
of beta blocker 
HbA1c 
> 6.4% start metformin 
< 6.4% no treatment 
BMI 
>25 kg/m2 lifestyle advice 
+ consultation of a 
dietician will be advised 
≤25 kg/m2 no 
action 
<7% continue therapy  
 
>7% add sitagliptin 
Figure 1. Flow chart tight control.
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Rheumatoid arthritis disease activity
Rheumatoid arthritis disease activity was assessed using the Disease Activity Score with 
28 joints counted (DAS28). This score included swollen joint count (28), tender joint 
count (28), VAS score (scale 0-100) indicating pain and discomfort due to RA, and the 
level of C-reactive protein (CRP). 
Laboratory measurements
A standardized set of measurements was performed in each subject. Blood samples 
were drawn after an overnight fast. Laboratory parameters were determined at the De-
partment of Clinical Chemistry, Franciscus Gasthuis, Rotterdam, the Netherlands. Renal 
and liver function tests as well as glucose, CRP, total cholesterol, HDL-C and TG were 
measured using Synchrom LX or DxC analyzers (Beckman Coulter, Anaheim CA, USA). 
LDL-C was calculated using the Friedewald formula if TG were below 4.00 mmol/l. Apo 
AI and apo B were determined by rate nephelometry using IMMAGE with commercially 
available kits (Beckman Coulter). The erythrocyte sedimentation rate (ESR) was mea-
sured using an Alifax Test 1 analyzer (Alifax, Padova, Italy).
Statistics
Data are given as mean ± standard deviation (SD) unless stated otherwise. Differences 
between groups were determined using the unpaired Student’s t-test or Chi-square test, 
where appropriate. In case of skewed variables (DAS28(-ESR), C-reactive protein and TG), 
the Mann-Whitney U test was used for comparisons between groups and the Wilcoxon 
signed ranks test for comparisons within groups. All statistical analyses were performed 
using PASW statistics version 18.0 (IBM SPSS Statistics, New York, United States). Primary 
endpoint of the FRANCIS study is progression of cIMT after five years of follow-up. Since 
the study is still in progress, for the present analysis we aimed to investigate levels of 
CVD risk factors after two years of follow-up and the number of patients that reached 
treatment targets. 
Results
General Characteristics
Table 1 shows the general characteristics of all included patients at baseline per group. 
In total 317 patients were randomized, 157 to usual care and 160 to tight control. Nine 
patients were included in the high-risk cohort. Two-year follow up data were available 
in 239 patients, 109 (69.4%) patients in the usual care group and 121 (75.6%) in the 
tight control group. In the tight control, group 3 patients died within the first two years 
of follow-up (probably not CVD related) and 27 patients ended study participation for 
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other reasons. In the usual care group 31 patients were lost to follow-up. No patients 
died in the usual care group. Nine patients in the tight control group and 17 patients in 
the usual care group were excluded for this analysis due to missing data (i.e. a missing 
visit at two year follow-up). 
The majority of the patients was female (n=222; 70%). Most patients (n= 268; 82%) 
were Dutch and currently in a relationship/marriage (n= 258 (79%)) and highly educated 
(college/university) (n=219; 69%). Participants in the tight control group were more 
often female compared to participants in the usual care group. There were no differ-
ences in other parameters between the groups at baseline. Baseline characteristics in 
the 239 patients that also had data at 2 years follow-up were comparable the baseline 
study population (Table 2) and show a significant difference in gender (i.e. more female 
patients in the tight control group) but no differences in other parameters. 
In Table 3 medication use at baseline is shown for the patients included in the 2-year 
analysis. There were no differences in the use of medication at baseline between the 
usual care and the tight control group. In both groups, very few patients used statins at 
baseline (4% and 6% for usual care and tight control, respectively).
Tight control versus usual care at 2-year follow-up
LDL-C decreased in the tight control group (3.3±0.9 mmol/l to 2.5±0.8 mmol/l; p<0.001) 
and in the usual care group (3.4±0.8 mmol/l to 3.1±0.9 mmol/l; p<0.001). The mean de-
Table 1. General characteristics at baseline.
Usual Care
(n=157)
Tight control
(n=160)
p-value
Male gender (n,%) 59 (38%) 36 (23%) 0.05
Age (yrs) 52±12 54±11 0.059
Body mass index (kg/m2) 26±5 26±4 0.78
Waist circumference (cm) 94±14 93±12 0.77
Smoking (n,%) 32 (20) 29 (18) 0.67
Systolic blood pressure (mmHg) 131±18 131±19 0.89
Total cholesterol (mmol/l) 5.4±1.0 5.4±1.0 0.90
LDL-C (mmol/l) 3.4±0.9 3.3±1.0 0.67
HDL-C (mmol/l) 1.46±0.41 1.52±0.41 0.18
Triglycerides (mmol/l) median (IQR) 1.11 (0.71-1.56) 0.98 (0.73-1.42) 0.52
Apolipoprotein AI (g/L) 1.67±0.37 1.70±0.37 0.91
Apolipoprotein B (g/L) 1.00±0.26 0.99±0.25 0.90
Fasting glucose (mmol/l) 5.4±0.6 5.5±0.6 0.63
HbA1C (mmol/mol) 35±4 35±4 0.52
C-reactive protein (mg/dl) median (IQR) 2.0 (1.0-6.0) 3.0 (1.0-6.0) 0.94
DAS28ESR median (IQR) 2.4 (1.7-3.4) 2.5 (1.6-3.2) 0.69
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crease in LDL-C was 2.7 times greater in the tight control group when compared to the 
usual care group (-0.99±0.99 mmol/l vs -0.37±0.76 mmol/l; p=0.03). After two years of 
follow-up, total cholesterol, LDL-C and apo B levels were significantly lower in the tight 
control group compared to usual care. There was a trend towards lower TG (p=0.05) and 
higher HDL-C (p=0.07) in the tight control group after 2 years. In total 72% (n=87) of the 
patients in the tight control group had an LDL-C <3.0 mmol/l after two years compared 
to 38% (n=41) in the usual care group (p<0.001).
The systolic blood pressure significantly decreased in the tight control group (132±19 
mmHg to 127±14 mmHg; p<0.004) but not in the usual care group (130±18 mmHg 
to 127±16 mmHg; p=0.078). However, the systolic blood pressure was comparable 
between both groups after 2 years. Systolic blood pressure treatment targets were 
reached in 75% (n=90) of the patients in the tight control group versus 70% (n=76) in 
the usual care group (p=0.46). Diastolic blood pressure treatment targets were reached 
in 73% (n=88) of the patients in the tight control group versus 70% (n=76) in the usual 
care group (p=0.66). In the tight control group BMI was significantly higher after 2 years 
compared to baseline and waist circumference was significantly lower (Table 2). No dif-
ferences were found in other traditional CVD risk factor after strict treatment or usual 
care (Table 2). 
In total, 8 patients (9%) in the usual care group started with statin treatment and 41 
patients (41%) in the tight control group (p<0.001). New anti-hypertensive drugs were 
initiated in 5 patients (5%) in the usual care group and 11 patients (9%) in the tight 
Table 3. Medication use at baseline.
Usual Care
(n=109)
Tight control
(n=121)
p-value
Lipid lowering drugs (n,%) 4 (4%) 7 (6%) 0.54
Anti-hypertensive drugs (n,%) 19 (17%) 26 (21%) 0.51
Use of 1 anti-hypertensive drug 4 (4%) 11 (9%) 0.11
Use of 2 anti-hypertensive drugs 13 (12%) 8 (7%) 0.25
Use of 3 anti-hypertensive drugs 2 (2%) 7 (6%) 0.18
NSAIDs (n,%) 41 (38%) 51 (42%) 0.49
Prednisone (n,%) 17 (16%) 13 (11%) 0.33
Methotrexate (n,%) 85 (78%) 85 (70%) 0.28
Hydroxychloroquine (n,%) 26 (24%) 26 (21%) 0.75
Sulphasalazine (n,%) 6 (6%) 3 (2%) 0.32
Anti-TNF (n,%) 39 (36%) 50 (41%) 0.34
Other biological (n,%) 4 (4%) 4 (3%) >0.99
Use of >1 DMARD, excl. biologicals and steroids (n,%) 23 (21%) 20 (17%) 0.50
Use of >1 DMARD, excl. steroids incl. biologicals (n,%) 51 (47%) 54 (45%) 0.89
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control group. Glucose lowering drugs were initiated in 1 patient of the tight control 
group. The number of smokers remained the same in two years time in both groups, 
despite active referral to the smoking cessation outpatient clinic of patients in the tight 
control group. 
Discussion
In this interim analysis we showed that treatment according to a tight treatment pro-
tocol for traditional CVD risk factors resulted in more frequent use of lipid lowering 
drugs and a greater decrease in LDL-C with a trend to improved TG and HDL-C levels, 
when compared to usual care. The number of patients that reached LDL-C treatment 
targets was significantly greater in the tight control group compared to usual care. Also 
blood pressure was significantly lower after two years in the tight control group, but 
not in the usual care group. The number of patients that reached treatment target for 
LDL-C and systolic blood pressure was approximately three quarters of the patients. 
This means that in 25% of the cases patients were not treated to target. The reason for 
this may be patient-related, i.e. non-adherence or unwillingness to take the prescribed/
recommended treatment, or doctor-related, i.e. not treating as strictly as the protocol 
describes for various reasons. Currently data on the reasons for not following the proto-
col are unavailable. We know that adherence to primary, and even secondary prevention 
in the general population is also poor (21, 22). In our study all participants willingly 
participated in this randomized controlled trial regarding CVD risk management, which 
may lead to relatively more adherent patients to be included compared to the general 
population. A previous report on adherence to prescribed CV medication reported high 
adherence rates of 90%, this is however self-reported (21). For other CVD risk parameters 
such as, smoking habits and body mass index no differences after two years of follow-up 
were found in either group. It is generally known that adherence to recommended life-
style changes are generally low, which may be the reason for this lack of improvement. 
We have shown previously that adherence to lifestyle recommendations in patients in 
the tight control arm varies between 56% and 68% (23). It is nevertheless surprising 
to see that the number of smokers stayed exactly the same, despite active referral to 
the outpatient clinic for smoking cessation. The number of patients using lipid lowering 
drugs and anti-hypertensive drugs increased in both the tight control and the usual care 
group. This may be due to the increased awareness of participating patients or their 
general practitioners. All general practitioners received a letter from the outpatient 
clinic of vascular medicine containing anthropometric and laboratory measurements of 
their patients including a brief explanation of the study and recommended treatment 
targets. But still, in the usual care group only few patients (n=8; 9%) were prescribed 
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lipid lowering drugs. Maybe the necessity of treating hypertension is perceived to be 
more important than the treatment of dyslipidemia by physicians, or patients, or there 
are differences in side-effects of the medications.
In conclusion, this study shows that a tight control treatment at the outpatient clinic 
resulted in a better overall lipid profile and a higher number of patients on statins and 
more patients reaching treatment targets regarding CVD risk reduction.
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Introduction
Over the last years the evidence on the increased cardiovascular disease (CVD) risk 
in rheumatoid arthritis (RA) has accumulated. The main question is how to lower this 
risk. Several RA specific risk factors such as disease activity, inflammatory markers and 
anti-CCP have been associated with increased carotid intima media thickness (cIMT) and 
CVD. These risk factors however do not fully explain the CVD risk and traditional CVD 
risk factors such as hypertension and hyperlipidemia should not be overlooked. To date 
it remains unclear what the exact influence of individual, RA specific, or traditional CVD 
risk factors is on the actual risk. In order to improve risk assessment, taking into account 
the evidence on the increased CVD risk in RA, several adaptations to the SCORE risk 
assessment model are made (Table 1). 
The main objectives of this thesis were:
1. To determine the impact of traditional CVD risk factors such as hypertension and 
hyperlipidemia on CVD risk and (subclinical) atherosclerosis in RA patients that do 
not have a history of CVD or diabetes mellitus. 
2. To determine patients believes on adherence to their advised CVD preventive treat-
ment. 
3.  To explore the presence of postprandial hyperlipidemia, as a novel risk factor, in RA 
patients 
Main findings
Objective 1: The impact of traditional CVD risk factors in RA patients
This aim was threefold: First, to assess what the prevalence of hypertension and hyper-
lipidemia is in RA patients with no prior history of CVD or diabetes mellitus. Second, to 
Table 1. National and international guidelines for CVD risk assessment in RA patients.
Adaptations to CVD risk assessment according to SCORE
EULAR guideline (2010) CVD risk* x 1.5 if at least two of following characteristics 
are present:
- > 10 years RA disease duration 
- RF and/or anti-CCP positivity 
- severe extra articular disease 
Dutch guideline for CVD risk management (2011) Age +15 years for all RA patients**
* According to SCORE and/or Framingham
** For assessment of CVD risk according to SCORE 
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determine which factors, RA specific or traditional CVD risk factors, are associated with 
subclinical atherosclerosis measured by carotid intima media thickness (cIMT) and to 
investigate which factors are associated with cIMT in RA compared with controls. Third, 
to investigate the effect of a tight, protocol based treatment of traditional CVD risk fac-
tors on (subclinical) atherosclerosis.
Prevalence of hypertension and hyperlipidemia in RA
Atherosclerosis is an inflammatory disease (1) and therefore, the inflammatory burden in 
RA patient is believed to play a role in the development of an excess CVD risk. However, 
traditional CVD risk factors should not be overlooked. Even in the case of secondary 
prevention, where the need for tight treatment regarding CVD risk factors is commonly 
known and accepted, a large number of patients remained above treatment target for 
hypertension and hyperlipidemia (2). In primary prevention in the general population 
an undertreatment of 50% of the patients has been reported (3, 4). The attention for 
primary prevention may even be lower in patients with a chronic disease that needs a 
continuous therapy and evaluation, such as RA. Several studies show that there is under-
diagnosis of traditional CVD risk factors in RA (4, 5). Our results, as described in Chapter 
3, are in line with these reports, but the prevalence of hyperlipidemia is markedly higher. 
Of the 327 included patients, 221 patients had a calculated CVD risk ≥10%. Of them 
185 (84%) had a LDL-C >2.5 mmol/l and were therefore eligible for treatment with lipid 
lowering drugs using current guidelines. Regarding hypertension 72 patients (32%), of 
the 221 with a CVD risk ≥10%, had a systolic blood pressure >140mmHg. Besides the fact 
that screening for risk factors might occur less in these patients, as explained above, an-
other reason for the underdiagnosis may be the unawareness of the current guidelines. 
When adapting the SCORE risk assessment according to EULAR recommendations (6) 
and even more when following CVRM guidelines (7), the CVD risk rises markedly which 
leads to a larger number of patients eligible for treatment. 
Association of cardiovascular risk factors with carotid intima media thickness 
In order to better understand the exact role of traditional and RA specific CVD risk factors 
we studied, in Chapter 5, the association of those CVD risk factors with subclinical ath-
erosclerosis measured by carotid intima media thickness. In multivariable analysis the 
only factor besides age, which was associated with cIMT was systolic blood pressure in 
RA patients (B=0.001 [-0.000-0.002]; p=0.003) and smoking in controls (B=0.101 [0.041-
0.162]; p=0.001). It is surprising that the average cIMT of both groups were comparable 
(0.556±0.120 mm and 0.573±0.134 mm for RA and controls, respectively) and within 
normal range. A reason for this lack of difference may be the fact that the RA patients in 
this study had low disease activity (median [IQR] DAS28=2.4 [IQR 1.6-3.2]). This reported 
DAS28 is lower than in previous studies investigating on cIMT in RA (8). In order to draw 
General discussion 119
8
more accurate conclusions on the role of RA disease activity on cIMT, an average DAS28 
over time is necessary to estimate the inflammatory burden. 
Effect of a tight control treatment protocol for traditional cardiovascular risk 
factors in rheumatoid arthritis patients
Regarding cardiovascular preventive medication in RA, there are some studies showing 
a favourable effect. Statin treatment effectively improves lipid levels in RA patients (9, 
10) and anti-hypertensive treatment with ACE-I and angiotensin II antagonists effec-
tively lower blood pressure and improves endothelial function in RA (11-13). Chapter 
7 described the results of a randomized clinical trial investigating traditional CVD risk 
factor treatment following a strict treatment protocol versus usual care after two years 
of follow-up. There was a significant decrease in blood pressure in the tight control 
group (132±19 mmHg vs. 127±14 mmHg; p<0.004), but not in the usual care group 
(130±18 mmHg vs. 127±16 mmHg; p<0.078). However, the systolic blood pressure was 
comparable between both groups after 2 years. LDL-C levels were significantly lower in 
the tight control group and the decrease was 2.7 times greater compared to the usual 
care group (-0.99±099 mmol/l vs -0.37±0.76 mmol/l; p=0.03). Treatment targets in the 
tight control group were reached in 75% (90 patients) for systolic blood pressure and in 
72% (87 patients) for LDL-C. To know the effects on subclinical atherosclerosis a longer 
follow-up period is needed. 
Objective 2: Patients believes on adherence
Although many doctors like to believe their patients follow all the given advice, we 
know that adherence to treatment recommendations varies according to the given 
advice and the result achieved for the patients. In the case of primary prevention adher-
ence rates of 44-66% have been described (14). Now that the excess CVD risk in RA has 
been accepted, it is important to investigate how to lower the risk. As stated above, 
besides a tight control treatment for RA, primary prevention by screening and treating 
traditional CVD risk factors is important. Since a large part of the success of primary 
prevention programs is based on patients adherence, we wanted to investigate the 
believes of the FRANCIS patients regarding their given advices. We chose to do this by 
using validated questionnaires (15, 16). The result of this questionnaire is discussed in 
Chapter 4. Self-reported adherence by a questionnaire may overestimate actual adher-
ence, but in contrast to more objective measurements like counting pills, questionnaires 
give a good insight in patients believes. In general, patients state to be able to follow 
the given advices: 69% of the patients (n=65) stated to follow the doctors advice exactly 
and only 5% said to be unable to do what the doctor told them to do. When taking a 
closer look by asking about adherence to specific recommendations, the percentage of 
adherent patients varied. Most patients took their prescribed medication (83-90%), but 
120 Chapter 8 
for lifestyle recommendations such as a diet or more exercise adherence rates varied 
from 56-86%. Besides the fact that these data are self-reported adherence rates, also the 
fact that all patients were willingly participating in a trial to lower CVD risk may result 
in higher adherence rates. Despite of these reasons for overestimation, adherence to 
lifestyle interventions are moderate.
Objective 3: Postprandial hyperlipidemia in RA
Postprandial hyperlipidemia is associated with the generation of atherosclerosis (17-19). 
Apolipoprotein (apo) B48 is the structural protein of intestinally derived chylomicrons 
(20) and therefore, a marker for postprandial hyperlipidemia. More specifically apo B48 
represents the exact number of circulating chylomicrons and chylomicron remnants. 
Based on several reports, the suggested upper limit of normal apo B48 levels is 5.7 mg/L 
in healthy controls (21). Our study is the first to report on apo B48 levels in RA patients. 
The median apo B found in our cohort was 8.6 mg/L [IQR 5.2012.5], which is markedly 
higher than the suggested upper limit in healthy controls. Moreover when creating 
tertiles based on apo B48 levels, the highest tertile showed apo B48 levels three times as 
high as reported in healthy controls. Also patients in this highest tertile were significantly 
more often anti-CCP and rheumatoid factor positive compared to the lowest tertile. 
Methodological considerations
The FRANCIS as a randomized controlled trial
The main strength of the FRANCIS study is that the impact of a pre-defined tight control 
regimen regarding lifestyle and drug treatment is compared to usual care (treatment as 
suggested by a patients own general practitioner), in an open label randomized control 
trial (RCT). A RCT is considered the optimal study design when two (or more) alternative 
interventions are compared in terms of effectiveness, because potential covariables and 
confounders are equally distributed among the alternative treatment strategies under 
consideration. Consequently, as a principle, the potential impact of these covariables 
and confounders on the outcome measures is reduced to random error, and the effect 
size, or systematic difference between alternatives, can be measured validly. Despite 
randomization, valid outcome measurement may be threatened by (1) incorrect ran-
domization procedure, (2) selective drop-out of patients (after randomization), and 
(3) invalid outcome assessment. The randomization procedure was simple and did not 
leave any room for incorrectness. Envelopes with randomization numbers and outcome 
were numbered. When a patients was randomized the first envelop available (i.e. the 
envelop with the lowest number) was taken. Furthermore, only a few physicians, who 
were all familiar with the study, were responsible for randomization. Selection bias may 
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occur as a result of selective drop out as stated second, in the first two years of FRANCIS 
there appears not to be a selective drop out. The number of patients that dropped out in 
both groups was similar after two years as described in Chapter 7 and there were no sig-
nificant differences between data at baseline when comparing all randomized patients 
to the patients that were still available after 2 years of follow-up. The third point men-
tioned is information bias. There are several levels in which information bias may play a 
role. First of all the FRANCIS is an open label study automatically implying information 
bias. A double blind approach however is not possible in this setting. Furthermore, the 
outcome of the FRANCIS depends on the usual care provided by general practitioners. 
This treatment may strongly depend on the individual general practitioner. Over the 
last years guidelines for primary prevention in RA patients have become more strict 
and strive after lower treatment targets compared to the FRANCIS protocol. This may 
minimize the effect measured in the FRANCIS study. In addition, general practitioners 
received a letter stating the participation in the study, the rationale for the study and the 
presence of CVD risk factors if applicable. This may have lead to increased awareness of 
the general practitioner as well, which may lead to better treatment and screening. The 
data reported in Chapter 7 however indicate that patients in usual care were overall not 
treated according to current guidelines. Data on the believes of general practitioners 
on the screening for and treatment of traditional CVD risk factors in RA are unavailable. 
External validity
The external validity of the FRANCIS depends on the inclusion and exclusion criteria. All 
patient with RA and without CVD younger than 70 years of age were able to participate. 
The only exclusion criterion was a chronic kidney disease (MDRD <30 ml/min). These 
criteria make the result widely applicable. However, the CVD risk of RA patients overall 
may be underestimated since patients with CVD were excluded. There are several spe-
cific characteristics in this cohort that limit the external validity. First of all most patients 
were Caucasian and highly educated. Secondly, patients in this cohort also followed a 
tight controlled treatment regimen regarding the RA disease activity, as is part of the 
standard care in the outpatient clinic of rheumatology. Since the ongoing inflammation 
as a result of RA disease activity may play a role in the CVD risk, our data is only gener-
able to patients in countries that have possibilities for high RA disease control.
Other considerations
Chapter 4 describes the results of a questionnaire. This may lead to information bias 
because this self-reported adherence may have overestimated actual adherence. The 
reason to use this method of measurement was primarily to investigate patients be-
lieves rather than the most accurate measurement of adherence itself. Furthermore, the 
cross-sectional design of the study makes it impossible to comment on adherence over 
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time. Adherence tends to decline over years and it would therefore be interesting to 
know how the self-reported adherence changes over time. 
Chapter 5 also has a cross-sectional study design. The reported associations therefore, 
do not give insight on the effect of individual risk factors on the development of (sub-
clinical) atherosclerosis. A longitudinal analysis at this point is not possible/informative 
due to the short follow-up period, but may be interesting in the future. 
New insights
The new insights acquired from this thesis are
- Hypertension and hyperlipidemia are highly prevalent in RA
- Hypertension is associated with cIMT in RA patients
- Patients believe they follow the recommendations regarding CVD risk management 
well. The exact self-reported adherence varies between the different recommenda-
tions provided by physicians.
- RA patients have very high apo B48 levels and patients with the highest apo B48 
levels are more often rheumatoid factor positive and/or anti-CCP positive. 
- A tight treatment protocol regarding traditional CVD risk factors results in a signifi-
cantly lower LDL-C compared to standard care. 
Recommendations for clinical practice
There have been numerous reports on the excess CVD risk in RA and to date more and 
more rheumatologists are aware of this increased risk. In daily practice however screen-
ing and treatment of this excess risk is not common practice. This may be partly because 
the exact role of known risk factors and the influence of currently unknown risk factors 
is subject of ongoing investigation. However, given the evidence that traditional CVD 
risk factors are highly prevalent, associated with subclinical atherosclerosis and improve 
in a tight control regimen, a routine screening and structured treatment is warranted. 
Recommendations for future research
The follow-up period of two years, described in this thesis, is too short to draw conclu-
sions on the effect of tight control of traditional CVD risk factors in RA on the develop-
ment of subclinical atherosclerosis. This is even more the case when investigating the 
effect on clinical atherosclerosis (i.e. cardiovascular disease/events/mortality). A longer 
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follow-up period is necessary and planned. The FRANCIS study will continue until all in-
cluded subjects have completed their 5 years of follow-up. In addition, it is likely that the 
FRANCIS study will be expanded for another 5 years of follow-up. This future research 
will give better understanding of the role and treatment of traditional CVD risk factor on 
the excess CVD risk in RA.
As described in detail in Chapter 3 and more briefly in other parts of this thesis, there 
is need for an accurate risk assessment tool in RA patients. Current risk assessment pro-
files such as SCORE and Framingham are not accurate in RA patients. In order to better 
assess the risk several adaptations to these models have been suggested. However, this 
still does not take into account the RA specific risk factors such as CRP levels or the 
presence of auto-antibodies. Recently Arts et al. investigated the performance of the 
SCORE risk model after recalibration and adaptation with additional RA–specific CVD 
risk factors. This did not lead to major improvements in the accuracy of CVD risk predic-
tion in RA. They also added RA specific CVD risk factors to the model, which resulted only 
in a modest improvement in discriminatory ability in comparison with the traditional 
SCORE (22). The lack of accurate risk assessment together with the uncertainty of the 
role of individual risk factors on CVD risk makes it difficult to implement a structured 
treatment advice in clinical practice. Therefore, further research in order to result in bet-
ter risk assessment is necessary. 
A remarkable and very interesting finding in the FRANCIS study is the high apo B48 
levels in RA. There is currently is no explanation why apo B48 levels are so high, despite 
low remnant cholesterol levels in RA, which would be interesting to explore in the fu-
ture. Since the use of currently known traditional and RA specific CVD risk factors has not 
resulted in better CVD risk assessment, novel, currently unknown CVD risk factors needs 
to be investigated. Apo B48 as a marker of postprandial hyperlipidemia may be such a 
novel marker in RA, which may improve CVD risk calculation in RA.
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Summary
This thesis aimed to give more insight in cardiovascular disease (CVD) risk and treatment 
and diagnosis of traditional cardiovascular risk factors in RA patients. Chapter 2 reviews 
current evidence on this topic. The main objectives of this thesis were: (1) To determine 
the impact of traditional CVD risk factors such as hypertension and hyperlipidemia on 
CVD risk and (subclinical) atherosclerosis in RA patients that do not have a history of CVD 
or diabetes mellitus. (2) To determine patients believes on adherence to their advised 
CVD preventive treatment. (3) To explore the presence of postprandial hyperlipidemia, 
as a novel risk factor, in RA patients. The first objective is addressed in chapter 3, 5 and 
7. The second objective is addressed in chapter 4 and the third objective is addressed 
in chapter 5. 
Chapter 3 describes the presence of hypertension and hyperlipidemia in the FRANCIS 
cohort at baseline. As reported previously in other studies, we found a high prevalence 
of CVD risk factors. The assessed CVD risk depended on the model used. When using the 
adaptations to the SCORE model as suggested in the Dutch guideline for cardiovascular 
risk management (CVRM), 221,of the 327 included patients had a calculated CVD risk 
≥10%. Of them 185 (84%) had a LDL-C >2.5mmol/l and were therefore eligible for treat-
ment with lipid lowering drugs using current guidelines. Of the few patients that already 
used statins at inclusion (14 patients) the vast majority (12 patients; 89%) did not reach 
recommended treatment targets. Regarding hypertension 72 patients (32%), of the 221 
with a CVD risk ≥10%, had a systolic blood pressure >140mmHg. 
In Chapter 4 patients believes on their adherence were investigated using question-
naires. Questionnaire were send to all patients included in the tight control arm with a 
minimum of 6 months follow up. The response rate was 82%, resulting in 111 question-
naires. The questionnaires consisted of two parts. In the first part patients were asked 
about adherence in general and the second part questioned adherence to specific 
advices. In the first part, asking about believes and adherence in general, patients stated 
overall to follow the advice without difficulty. 69% of the patients (n=65) stated to follow 
the doctors advice exactly and only 5% said to be unable to do what the doctor told 
them to do. Part two of the questionnaire was on adherence to specific recommenda-
tions. Most patients took their prescribed medication (83%-90%), but for lifestyle recom-
mendations such as a diet or more exercise adherence rates varied from 68%-56%.
In Chapter 5 the association of several CVD risk factors, both traditional and RA spe-
cific, on subclinical atherosclerosis measured by carotid intima media thickness (cIMT) 
was investigated. In univariate regression analysis several traditional CVD risk factors 
were associated with cIMT in RA patients and in controls. In RA patient also a significant 
association between cIMT and RA disease duration was found. The diagnosis RA itself 
was not associated with cIMT. In multivariable analysis the only factor, besides age, that 
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was associated with cIMT was systolic blood pressure in RA patients (B=0.001 [-0.000-
0.002]; p=0.003) and smoking in controls (0.101[0.041-0.162]; p=0.001). The average 
cIMT of both groups are comparable (0.556±0.120 mm and 0.573±0.134 mm for RA and 
controls respectively) and within normal range. A reason for this lack of difference may 
be the fact that the RA patients in this study have low disease activity (median [IQR] 
DAS28=2.4 [IQR 1.6-3.2]). 
Chapter 6 describes the first report on apolipoprotein B48 (apo B48) levels in RA 
patients. Apo B48 is the structural protein of chylomicrons and serum concentrations 
are increased in conditions associated with systemic inflammation. The median apo B48 
concentration in our cohort was 8.6 mg/L [IQR 5.2-12.5mg/L] which is markedly higher 
than the suggested normal values for healthy controls. Furthermore patients in the 
highest apoB48 tertile are, compared to the lowest tertile, more often rheumatoid factor 
positive 75% [n=72] vs. 58% [n=62]; p=0.04) and anti-CCP positive (75% [n=62] vs. 59% 
[n=59]; p=0.005). Despite the high apo B48, remnant cholesterol concentrations and 
fasting plasma triglycerides were relatively low (0.52±0.26 mmol/l and 1.25±0.88 mmol/l 
respectively), which indicates that chylomicron remnant clearance may be delayed in 
RA. 
Chapter 7 shows data after two years of follow up in the FRANCIS. Both patients in 
the tight control group (3.3±0.9 mmol/l vs. 2.5±0.8mmol/l; p<0.001) and in the usual 
care group (3.4±0.8 mmol/l vs. 3.1±0.9 mmol/l; p<0.001) had a significantly lower LDL-C, 
but the decrease was significantly greater (2.7 times) in the tight control group (- 0.4±0.8 
mmol/l vs -1.0±1.0 mmol/l; p=0.03). Furthermore, significantly more patients reached 
treatment the target for LDL-C compared to usual care. Also systolic blood pressure 
was significantly lower in the tight control group (132±19 mmHg vs. 127±14 mmHg; 
p<0.004) and treatment targets were reached in 75% (n=90) of the patients. In the usual 
care group the decrease in blood pressure did not reach statistical significance (130±18 
mmHg vs. 127±16 mmHg; p<0.078) and less patients reached treatment targets (70%; 
n=76). This difference in patient numbers reaching targets was not significantly different.
Overall patients in the tight control arm were more treat-to-to target resulting in 
significantly lower LDL-C and systolic blood pressure. Longer follow-up is necessary to 
evaluate the effect of this treatment difference on subclinical atherosclerosis. 
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Introductie
Reumatoïde artritis (RA) is een auto-immuun ziekte waardoor er ontstekingen in 
meerdere gewrichten (artritis) kunnen ontstaan. Het is gebleken dat patiënten met RA 
een verhoogd risico hebben op hart- en vaatziekten wat inhoudt dat deze patiënten 
vaker dan normaal een myocardinfarct (hartinfarct), een beroerte of perifeer vaatlijden 
(etalage-benen) ontwikkelen. Nu het verhoogde cardiovasculaire (CV) risico in RA 
meermalen is aangetoond, is het belangrijk om de factoren die dit risico in RA patiënten 
bepalen in kaart te brengen. De ontwikkeling van hart- en vaatziekten begint o.a. met 
atherosclerose (aderverkalking), waardoor de slagaders dichtslibben. De ontwikkeling 
van atherosclerose is deels een inflammatoir (ontstekings) proces, waardoor het voor 
de hand ligt te denken dat de chronische ontsteking die bij RA patiënten aanwezig is 
de veroorzaker van het verhoogde CV risico is. Toch kunnen we hiermee niet volledig 
het verhoogde CV risico verklaren. De zogenoemde traditionele CV risicofactoren zoals 
hypertensie (hoge bloeddruk), hypercholesterolemie (verhoogd cholesterol), diabetes 
mellitus (suikerziekte), overgewicht en roken, zijn ook bij RA patiënten aanwezig. Deze 
risicofactoren lijken zich niet hetzelfde te gedragen als in de algemene populatie. On-
dergewicht, zich uitend in een body mass index (BMI) van <20kg/m2, is in RA patiënten 
bijvoorbeeld, in tegenstelling tot de algemene populatie, geassocieerd met een ver-
hoogde CV mortaliteit. Over de jaren heen is er een betere en striktere behandeling voor 
de reumatische gewrichtsontstekingen ontwikkeld wat leidt tot minder inflammatie. Dit 
zou theoretisch kunnen leiden tot een vermindering van het CV risico. Tot op heden is 
dit echter nog niet aangetoond.
Het is niet bekend wat de lange termijn effecten zijn van een strikte, geprotocolleerde 
behandeling van de traditionele CV risicofactoren op de uiteindelijke ontwikkeling van 
hart- en vaatziekten bij patiënten met RA. Zolang de risicofactoren niet goed in kaart 
gebracht zijn, is het lastig een adequaat CV risico predictiemodel te ontwikkelen voor 
patiënten met RA. Tot op heden wordt voor RA geadviseerd om bestaande CV risico 
predictiemodellen (SCORE of Framingham) te gebruiken en deze aan te passen voor 
RA. Hiervoor bestaan meerdere voorstellen, bijvoorbeeld door het berekende risico met 
1.5 te vermenigvuldigen of door 15 levensjaren bovenop de werkelijke leeftijd van de 
patiënt te tellen. Ondanks dat iedereen zich realiseert dat dit geen nauwkeurige inschat-
ting van het risico geeft, is er tot op heden geen betere manier gevonden. 
In Hoofdstuk 2 wordt het reeds bestaande bewijs en laatste inzichten rondom het 
verhoogd CV risico in RA besproken. In het verdere proefschrift worden de prevalentie 
van traditionele cardiovasculaire risicofactoren, de behandeling van deze factoren en 
het effect op atherosclerose in RA beschreven. Al deze bevindingen zijn gebaseerd 
op de FRANCIS studie, een studie die speciaal hiervoor is opgezet door de afdelingen 
Reumatologie en Vasculaire Geneeskunde binnen het Franciscus Gasthuis.
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Globale doelen van het proefschrift:
1. Bepalen wat de impact van traditionele CV risicofactoren zoals hypertensie en hy-
percholesterolemie is op het CV risico en atherosclerose bij RA patiënten, die niet 
bekend zijn met hart- en vaatziekten of met diabetes. 
2. Bepalen wat patiënten zelf denken over hun therapietrouw ten aanzien van gegeven 
adviezen om hun CV risico te verminderen. 
3. Onderzoeken of er bij RA patiënten sprake is van een postprandiale hyperlipidemie 
(een sterke verhoging van vetzuren na een maaltijd), een mogelijke, nog onbekende 
risicofactor in RA. 
Onderbehandeling van hypertensie en hypercholesterolemie in RA
In Hoofdstuk 3 wordt de aanwezigheid van traditionele CV risicofactoren beschreven. 
Zoals reeds eerder gepubliceerd was, vonden wij ook een hoge prevalentie (vóórkomen) 
van traditionele CV risicofactoren. De exacte prevalentie hangt af van de gehanteerde 
afkapwaarden, namelijk wat een acceptabele bloeddruk of LDL-cholesterolwaarde is en 
die hangt weer af van de à priori kans op de ontwikkeling van hart- en vaatziekten. 
Zo is het advies om naar een LDL-cholesterol van ≤2.5 mmol/l te streven bij patiënten 
met een CV risico van >10% binnen 10 jaar. Als het risico lager is, is behandeling niet 
noodzakelijk en is er dus in strikte zin geen sprake van hypercholesterolemie. Wij von-
den dat er bij 84% van die patiënten (n=172) sprake was van een LDL-cholesterol >2.5 
mmol/L. Wanneer we keken naar de bloeddruk had 32% van de patiënten (n=72) met 
een CV risico ≥10% een systolische bloeddruk boven de gestelde grens van 140mmHg. 
De oorzaken voor deze hoge aantallen is tweeërlei. Veel patiënten met hypertensie en/
of hypercholesterolemie worden niet herkend en daardoor niet behandeld. Wanneer RA 
patiënten wel behandeld worden, bleken zij in de meerderheid van de gevallen niet de 
streefwaardes zoals in richtlijnen zijn vastgelegd te halen, wat duidt op onderbehande-
ling. Deze feiten vragen om een betere screening en behandeling van traditionele CV 
risicofactoren bij RA patiënten. Door het gebruik van een CV risico predictiemodel is het 
gemakkelijker te bepalen welke patiënten wel en welke patiënten niet in aanmerking 
komen voor verdere medicamenteuze therapie. Omdat, zoals hierboven beschreven, 
een goed werkend CV risico predictiemodel specifiek voor RA patiënten nog niet voor 
handen is, moet er gebruik worden gemaakt van de voorgestelde aanpassingen van 
bestaande modellen. 
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Therapietrouw ten aanzien van cardiovasculaire preventie in RA
Wanneer we patiënten meer medicatie voorschrijven en leefstijladviezen geven is het 
altijd de vraag of deze adviezen opgevolgd worden en wat patiënten hiervan vinden. In 
Hoofdstuk 4 werd de visie van RA patiënten ten aanzien van de gegeven adviezen om 
hun CV risico te verminderen onderzocht door middel van een vragenlijstonderzoek. Alle 
RA patiënten uit de strikte CV risico reductiegroep binnen de FRANCIS studie kregen een 
vragenlijst. Deze vragenlijst bestond uit een eerste deel, met algemene vragen ten aan-
zien van het opvolgen van de gegeven adviezen, en een tweede deel waarin elk advies 
apart werd ondervraagd. Hieruit bleek dat patiënten het, in het algemeen, niet lastig 
vonden om de gegeven adviezen op te volgen. In totaal gaf 75% van de ondervraagden 
aan het gemakkelijk te vinden wat de dokter hen aanraadde. Wanneer specifiek werd 
ingegaan op de afzonderlijke adviezen bleken er echter grote verschillen afhankelijk van 
het gegeven advies. Het advies een speciaal dieet te volgen werd door 68% gevolgd, 
echter het advies om aan meer lichaamsbeweging te doen werd slechts in 56% van de 
RA patiënten opgevolgd. Medicamenteuze therapie leek goed te worden nagevolgd. De 
overgrote meerderheid (90%) gaf aan de tabletten die voorgeschreven werden ook in 
te nemen. Opvallend was dat RA patiënten hun CV risico veel lager inschatten dan het 
daadwerkelijk berekende CV risico. Mogelijk dat dit verschil van inzicht ook bijdraagt 
aan de relatief lage therapietrouw wat betreft leefstijladviezen.
Factoren van invloed op subklinische atherosclerose in RA
In Hoofdstuk 5 werden de baseline data van de FRANCIS studie samengevoegd met 
data van controle patiënten uit een observationele studie binnen dezelfde afdeling 
Vasculaire geneeskunde. Deze controle patiënten waren ook patiënten zonder hart- en 
vaatziekten of diabetes mellitus, maar in tegenstelling tot de RA patiënten van de FRAN-
CIS hadden de controle patiënten geen RA. De mate van subklinische atherosclerose, 
dat wil zeggen de aanwezigheid van atherosclerose zonder dat het al tot klachten lijdt, 
werd gemeten met behulp van echografie. Hiermee werd dan de dikte van de intima 
en de media (onderdelen van de vaatwand) van de carotiden (halsslagaders) gemeten, 
wat wordt uitgedrukt als de intima media dikte (IMT). Vergeleken werd tussen RA en 
controle patiënten welke factoren geassocieerd waren met de IMT. In tegenstelling 
tot wat verschillende malen in de literatuur is gepubliceerd, vonden wij geen verschil 
in IMT tussen de RA patiënten en de controle patiënten. De gemiddelde IMT van de 
RA patiënten was 0.556±0.120mm, wat beschouwd mag worden als een normale IMT. 
Vervolgens hebben wij door middel van regressie analyse onderzocht welke parameters 
bijdroegen aan de hoogte van de IMT. Dit bleek voor beide groepen verschillend. Bij de 
138 Chapter 10 
controlegroep was roken geassocieerd met IMT, terwijl dit bij RA patiënten niet zo was. 
Voor de systolische bloeddruk (de bovendruk) was dit andersom. Deze was bij RA pati-
enten geassocieerd met de IMT en bij controle patiënten niet. Wat wel bij beide groepen 
duidelijk naar voren kwam was dat de leeftijd de belangrijkste voorspeller bleek bij de 
ontwikkeling van subklinische atherosclerose. Hiermee lijken zowel de bloeddruk als 
de leeftijd een sterke bijdrage te leveren aan de ontwikkeling van hart- en vaatziekten 
binnen RA. 
Verhoogd aantal circulerende chylomicronen in RA
Omdat tot op heden de exacte spelers in het veld van hart- en vaatziekten bij RA 
patiënten nog niet geheel bekend is, beschreven wij in Hoofdstuk 6 een potentiële 
CV risicofactor, namelijk apolipoproteïne (apo) B48. Iedere keer als we eten worden 
cholesterol en vetzuren vanuit de darm afgegeven via de lymfe aan het bloed middels 
water (of in bloed) oplosbare partikels genaamd chylomicronen. Iedere afzonderlijke 
chylomicron heeft precies één apo B48 als structuureiwit. Door apo B48 in het bloed te 
meten kan een indruk verkregen worden van de hoeveelheid circulerende chylomicro-
nen. Het bijzondere van chylomicronen is dat zij een ontstekingsreactie in de bloedbaan 
veroorzaken iedere keer wanneer wij eten, maar andersom kunnen chylomicronen bij 
inflammatie ook weer vaker verhoogd zijn. Chylomicronen induceren atherosclerose via 
directe afgifte van cholesterol in de vaatwand in combinatie met het induceren van een 
lokale ontstekingsreactie. Tot op heden was niet bekend of het metabolisme van chy-
lomicronen gestoord was in RA als mogelijke verklaring voor het verhoogde CV risico. 
We hebben het apo B48 gemeten in de nuchtere toestand bij alle RA patiënten 
die deelnamen aan de FRANCIS studie. Wij vonden dat apo B48 in RA patiënten sterk 
verhoogd was, hoger dan eerder gerapporteerde waardes bij gezonde vrijwilligers of 
patiënten die reeds bekend waren met hart- en vaatziekten. Dit was extra bijzonder aan-
gezien de triglyceriden (vetzuren) welke getransporteerd worden door chylomicronen, 
juist niet verhoogd waren in RA patiënten. Dit betekent dat er in RA patiënten relatief 
veel chylomicronen, maar met een geringe hoeveelheid triglyceriden en dus kleinere 
diameter, circuleren in de bloedbaan. Mogelijk dat dit zou kunnen passen bij een ver-
traagde opruiming van de chylomicronen, terwijl de verwerking van de triglyceriden in 
de postprandiale staat wel goede doorgang vindt. RA patiënten die positief waren voor 
reumafactoren (reumafactor en anti-CCP) bleken ook een hoger apo B48 te hebben. Het 
verhoogd aantal circulerende chylomicronen in RA kan dus een extra verklaring zijn 
voor het verhoogde CV risico in RA.
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Effect van strikte primaire CV preventie na 2 jaar
We weten nu dat het CV risico verhoogd is bij RA patiënten en dat hypercholesterolemie 
en hypertensie hiervoor belangrijke factoren zijn. Wat de effecten zijn van een gestructu-
reerde, strenge behandelwijze van de traditionele CV risicofactoren op het uiteindelijke 
risico op hart- en vaatziekten en het effect op subklinische atherosclerose is onduidelijk. 
Het primaire doel van de FRANCIS studie is om deze vraag te beantwoorden. In Hoofd-
stuk 7 worden de resultaten van strikte CV preventieve maatregelen versus standaard 
behandeling na twee jaar follow-up gepresenteerd. In beide groepen bleek dat het LDL-
cholesterol na twee jaar significant lager was dan bij start van de studie. De daling was 
echter 2.7 keer groter voor de strikt behandelde groep. Voor bloeddruk bleek er alleen 
een significante daling te zijn in de strikt behandelde groep en niet in de standaard 
groep. Verder werd duidelijk dat de RA patiënten in de strikte groep duidelijk meer 
cholesterolverlagende medicatie kregen voorgeschreven (41 patiënten vs. 8 patiënten 
in de standaard groep). Voor bloeddrukverlagende medicatie was dit minder duidelijk. 
Conclusie
Na 2 jaar FRANCIS onderzoek is gebleken dat traditionele CV risicofactoren zoals hyper-
tensie en hypercholesterolemie veel voorkomen bij RA patiënten en (meer) aandacht 
verdienen. 2 jaar geprotocolleerde strikte CV leidde tot een grotere bloeddrukverlaging 
en verlaging van het cholesterol. Een belangrijke nieuwe vraag is opgekomen, namelijk 
waarom het chylomicronen metabolisme in RA gestoord is en wat het belang hiervan 
is. Tot slot moeten we als arts nooit vergeten dat ook de patiënt zijn eigen gevoel en 
overtuigingen heeft. Dit resulteert niet altijd in het gewenste gedrag vanuit de arts 
bezien. De perceptie van de patiënt moet daarom nooit uit het oog verloren worden. 
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